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Abstract 
Chitosan, a polymer derived from crustacean chitin, has a number of properties that      
make it potentially valuable as a pharmaceutical excipient. In the studies described, 
microcrystalline chitosan (MCCh), a highly crystalline grade of chitosan base, was 
evaluated for the first time as an excipient. The first objective was to determine its 
properties in vitro as a gel-forming and drug release rate controlling excipient in granules, 
and as a mucoadhesive polymer. The properties of MCCh were compared with those of 
conventional chitosan, which is predominantly amorphous. Attention was also given to the 
effects of the molecular weight (Mw) and degree of deacetylation (DD) of MCCh on its 
properties. The ultimate objective was to evaluate, in studies on human volunteers, whether 
MCCh granules could be useful as slow-release systems for gastro-retentive drug delivery. 
Drug release in vitro could be controlled by altering the amount and grade of 
chitosan in the granules. Increasing the chitosan content decreased the release rate after the 
formation of chitosan gels in an acidic environment. MCCh had a more marked retardant 
effect than conventional chitosan, because of its superior gel formation. Retardation of 
drug release increased with the Mw of MCCh but DD had no marked effect. A slow release 
was achieved with model drugs that are slightly soluble in acidic environments (ibuprofen, 
furosemide). With a readily soluble drug (paracetamol) retardation of drug release was 
only slight. All the chitosans studied had fairly marked mucoadhesive tendencies in vitro 
(porcine oesophagus preparations). Adhesive strength increased with the Mw of chitosan, 
while other variables (DD and crystallinity) had no marked effects. 
Bioavailability studies showed that use of MCCh granules in gelatine capsules is a 
simple way of preparing slow-release dosage forms of slightly soluble drugs, provided the 
drug concerned, like ibuprofen, is absorbed throughout the gastrointestinal tract (gi-tract). 
With furosemide, a drug that is specifically absorbed in the upper gi-tract, the amounts 
absorbed decreased with release rate in vitro. This indicates that the drug was being 
released beyond its “absorption window”. Gamma scintigraphic investigations revealed 
that MCCh granules were not retained in the stomach to sufficiently reproducible extents; 
adhesion of MCCh onto gastric mucosa took place only occasionally. Adherence of the 
formulation to the oesophagus in one volunteer suggests that problems could arise from the 
type of formulation studied. The results of in vivo studies demonstrated that MCCh can be 
used to prepare slow-release systems but not gastro-retentive formulations. The results of 
dissolution and mucoadhesion tests in vitro did not allow adequate prediction of the in vivo 
behaviour of MCCh formulations. This underscores the importance of conducting 
biopharmaceutical studies at an early stage during the evaluation of new excipients. 
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11. Introduction 
Chitosan is a cationic polymer derived from the chitin of crustaceans. Its use in various 
applications has received considerable attention. One obvious advantage of this material is 
that it can be obtained from ecologically sound natural sources, namely crab- and shrimp-
shell wastes. Chitosan has been widely studied in the biomedical field, and has been found 
to be highly biocompatible (Muzzarelli et al., 1988). To mention only some areas of 
investigation, chitosan has been studied as a wound dressing (Loke et al., 2000; Mi et al., 
2001), as a haemostatic material (Rao and Sharma, 1997; Hoekstra et al., 1998) in the form 
of gels or sponges, and as sutures, in the form of fibres (Qin and Agboh, 1998). Some 
chitosan-based products, e.g. wound dressings (Illum, 1998), have reached the market. 
Chitosan has also been marketed throughout the world in non-medical products, as a fat-
binder in cholesterol-lowering and slimming formulations (Shahidi et al., 1999). It has 
been claimed that chitosan entraps lipids in the intestine, because of its cationic nature 
(Kanauchi et al., 1995; Wuolijoki et al., 1999). Chitosan may also have technical 
applications, including, e.g., use as a seed coating and nitrogen source in agriculture, and 
as an adsorbent for water-purification (Li et al., 1992). 
In recent decades there has also been considerable interest in the pharmaceutical 
field in using chitosan as an excipient, in various applications. In addition to the good 
biocompatibility of chitosan and the abundance of natural sources of the material, chitosan 
has a number of desirable properties that make study of it interesting. Because it is a 
polycationic polymer, chitosan forms gels most readily in acidic environments, such as that 
in the stomach. This makes chitosan interesting in relation to the development of slow-
release dosage forms for oral administration. The mucoadhesive properties of chitosan, 
illustrated by its ability to adhere for instance to porcine gastric mucosa in vitro (Gåserød 
et al., 1998), could allow site-specific drug delivery. These desirable properties of chitosan 
have recently led to increasing interest in the development of slow-release formulations for 
gastro-retentive drug delivery. Chitosan-based dosage forms of this kind could be useful in 
relation, e.g., to the administration of antibiotics used for eradication of Helicobacter 
pylori from the stomach (Shah et al., 1999; Remuñan-López et al., 2000). 
Chitosan is produced in grades that differ in their physicochemical properties, and as 
a base or a salt of a base. The existence of different grades could also be valuable. It seems 
that properties of chitosan-based dosage forms could be controlled by altering the grade of 
chitosan in formulations. The effects of chitosan on drug release rate (Goskonda and 
Upadrashta, 1993; Mi et al., 1997; Sabnis et al., 1997) and the capacity of chitosan for 
mucoadhesion (Lehr et al., 1992; He et al., 1998) depend on properties such as molecular 
2weight and degree of deacetylation of chitosan. Chitosan base seems likely to be more 
useful than chitosan salts in relation to development of slow-release formulations because 
it is in general less soluble. 
Microcrystalline chitosan (MCCh) may be particularly valuable as an excipient. 
MCCh is a highly crystalline grade of chitosan base (Struszczyk, 1987), which can be 
prepared on a large scale using a method developed by the Finnish company Novasso 
(Finnish Pat. FI83426, 1991). MCCh has been studied in relation to various technical 
applications (Struszczyk and Kivekäs, 1992) and in cholesterol-lowering formulations 
(Wuolijoki et al., 1999) but not as a pharmaceutical excipient before the studies described 
here were carried out. Most drug formulation studies involving chitosans have used 
material produced commercially by conventional methods. Chitosans of this kind are fairly 
amorphous. However, Sabnis et al. (1997) reported that increasing the crystallinity of 
chitosan could offer advantages in relation to manufacturing process of pharmaceutical 
formulations, e.g. by making the chitosan more suitable for direct compression into tablets. 
Perhaps more significantly, the crystallinity of a chitosan could affect the behaviour of a 
formulation in which it was incorporated. Effects of the crystallinity of chitosan therefore 
required evaluation. One specific property of MCCh is its high capacity for retaining water 
(Struszczyk, 1987). This property could be advantageous in relation to the development of 
slow-release formulations because it might facilitate the formation of gels that would 
control drug release. The pronounced ability of MCCh to form hydrogen bonds 
(Struszczyk, 1987; Struszczyk and Kivekäs, 1992) could theoretically result in efficient 
mucoadhesion by MCCh. The properties of MCCh mentioned made it particularly 
interesting for study as a hydrophilic excipient controlling rate of drug release from 
formulations that were also intended to be mucoadhesive in the stomach. 
It is obvious that no conclusions regarding the potential of MCCh, or any other         
grade of chitosan, as an excipient in drug delivery systems can be reached until 
biopharmaceutical studies have been conducted. A major defect in many previous studies 
is that only in vitro methods have been employed in determining the properties of chitosan-
based formulations. Only in some studies in animals have attempts been made to 
demonstrate the value of chitosan as a gel-forming polymer that could control rate of drug 
release from oral dosage forms (Miyazaki et al., 1988a,b), and to evaluate whether 
chitosan-based formulations were gastro-retentive (Remuñan-López et al., 2000). It is, 
however, well known that results of in vitro studies, and even results of animal         
studies, often fail to predict fate of a formulation in man (Davis and Wilding, 2000). 
Biopharmaceutical studies in human volunteers are therefore important. Until the studies 
described here were carried out, no information was available about the adhesion of 
chitosan to the mucosa of the human stomach or whether chitosan-based formulations had 
potential as slow-release systems for gastro-retentive drug delivery in man. 
31.1. Chitosan 
1.1.1. Origin of chitosan 
One reason why chitosan has become of interest is undoubtedly because it can be obtained 
from natural sources that are abundant and renewable. Chitosan is prepared from chitin, 
the polymer second most abundant in nature after cellulose (Roberts, 1992). Chitin is the 
primary structural component of the outer skeletons of crustaceans, and of many other 
species such as molluscs, insects and fungi. The role played by chitin is similar to the roles 
played by cellulose in plants and collagen in higher animals. It is a reinforcing material, 
which occurs in three polymorphic forms, Q-, R- and S-chitin. Where hardness in needed Q-
chitin is found, where flexibility is required R- and S-chitin occur. Chitin is inert in aqueous 
environment. This property limits the use of chitin as such. Chitosan is prepared from 
chitin to obtain a more reactive polymer. 
Chitosan is most commonly obtained from crustacean chitin, from crab- and shrimp-
shell wastes (Roberts, 1992; Shepherd et al., 1997). Chitin accounts for approximately 70% 
of the organic compounds in such shells. In preparing chitosan, ground shells are treated 
with alkali and acid to remove proteins and minerals, respectively, after which the extracted 
chitin is deacetylated to chitosan by alkaline hydrolysis at high temperature. Preparation of 
chitosan from crustacean-shell wastes is economically feasible and ecologically desirable 
because large amounts of shell wastes are available as a by-product of the food industry. 
Production of chitosan from these is inexpensive and easy. It has also been suggested that 
other sources of chitin, e.g. chitin from squid pens, may be valuable in relation to the 
preparation of chitosan (Shepherd et al., 1997; Rhazi et al., 2000). Chitosan as such is rare 
in nature, except in certain fungi. In recent years, there has been increasing interest in the 
production of chitosan from fungi, using fermentation methods (Nwe et al., 2002). 
1.1.2. Physicochemical properties of chitosan 
Structure. Chitosan is a linear polysaccharide consisting of ß (1-4)-linked 2-amino-2-
deoxy-D-glucose (D-glucosamine) and 2-acetamido-2-deoxy-D-glucose (N-acetyl-D-
glucosamine) units (Fig. 1). The structure of chitosan is very similar to that of cellulose 
(made up of ß (1-4)-linked D-glucose units), in which there are hydroxyl groups at C2 
positions of the glucose rings. 
The term chitosan is used to describe a series of polymers of different degrees of 
deacetylation (DD), defined in terms of the percentage of primary amino groups in the 
polymer backbone, and average molecular weights (Mw) (Roberts, 1992). The DD of 
chitosan is usually between 70 and 95%, and the Mw between 10 and 1000 kDa. Changing 
4the reaction conditions during the manufacture of chitosan from chitin can alter the DD 
and Mw of chitosan. The chitosan polymer produced using conventional commercial 
manufacturing methods is fairly amorphous (Struszczyk, 1987; Genta et al., 1995; Portero 
et al., 1998; Mura et al., 2003). The crystallinity of the polymer can be increased using the 
method described by Struszczyk (1987), which results in microcrystalline chitosan 
(MCCh). The method is based on precipitation of MCCh from acidic solutions of 
conventional chitosan. The crystallinity of MCCh manufactured using this method is up to 
30% greater than that of conventionally prepared chitosan, the crystallinity index of which 
is typically less than 60% (Struszczyk, 1987). The Finnish company Novasso has 
developed a continuous method (Finnish Pat. FI83426, 1991) for production of MCCh on 
a large scale. The DD of the MCCh produced typically ranges from 70 to 95%, and the  
Mw from 10 kDa to 300 kDa. MCCh is available as a base. Conventional chitosan is 
available both as a base and as a salt, e.g. the hydrochloride, malate or glutamate. 
Figure 1. Structural units of chitosan and its parent substance chitin. Chitin consists mostly 
of N-acetyl-D-glucosamine –units (left). During the preparation of chitosan most units are 
deacetylated to D-glucosamine –units (right). 
Behaviour in aqueous media. Chitosan, which contains a number of amino groups in 
its polymer backbone, is a polycationic base in acidic aqueous environments. A cationic 
character is rare in polysaccharides found in nature, which makes chitosan an interesting 
material for study. Several investigators (Cölfen et al., 2001; Berth and Dautzenberg, 
2002) are currently characterizing chitosan in aqueous media in depth, from a macro-
molecular point of view. 
The D-glucosamine unit has a pKa value of 7.5 (Roberts, 1992). The basic nature of 
chitosan depends on its degree of deacetylation, and the pKa value for the polymer is 
around 6.5. Chitosan base dissolves slowly in acidic and slightly acidic aqueous solutions. 
If the pH of a solution is increased to close to neutral, the base precipitates from the 
solution. Low-molecular-weight chitosans (Mw approximately 10 kDa or below) and 
chitosan salts (e.g. hydrochlorides) may be more readily soluble. Chitosan is also 
hydrophilic, retaining water in its structure and forming gels spontaneously. Gel formation 
5takes place at acidic and slightly acidic pH values, because of the cationic nature of 
chitosan. Chitosan gels increase in viscosity as molecular weight or amount of polymer 
increase (Roberts, 1992; Kristl et al., 1993). A decrease in the pH increases viscosity, 
apparently because the conformation of chitosan is more extended (random coil) at low pH 
values, because of repulsive forces between positively charged amino groups (Tsaih and 
Chen, 1999). Viscosities also increase as the degree of deacetylation increases, because the 
polyelectrolytic characteristics of the chitosan become more marked. Chitosan gels exhibit 
pseudoplastic flow, which means that their viscosities decrease as shear force increases 
(Senel et al., 2000). Chitosan gels degrade gradually, as the chitosan dissolves. 
1.1.3. Chitosan in pharmaceutical applications 
Chitosan has received considerable attention as a possible pharmaceutical excipient in 
recent decades (Table 1). It has been evaluated in both conventional excipient applications, 
e.g. as a directly compressible diluent in tablets (Sawayanagi et al., 1982a,b), as a binder in 
wet granulation (Upadrashta et al., 1992), and in novel applications, e.g. as a carrier for 
mucosal delivery of antigens in connection with oral vaccination (Van der Lubben et al., 
2001a,b; Chew et al., 2003). Chitosan has also recently been approved by the authorities, 
and a monograph relating to chitosan hydrochloride was included in the fourth edition of 
the European Pharmacopoeia (2002). 
Several properties of chitosan make it potentially valuable as a pharmaceutical 
excipient. Good biocompatibility and low toxicity of chitosan (Arai et al., 1968; Muzzarelli 
et al., 1988; Knapczyk et al., 1989; Kim et al., 2001), and the fact that sources of chitosan 
are abundant, are properties that any new excipient material should have. One property that 
makes chitosan particularly interesting for study as an excipient is its ability to become 
hydrated and form gels in acidic aqueous environments. Because of its gel-forming ability, 
a major area of interest since studies began has been use of chitosan to prepare slow-
release drug delivery systems. Chitosan has been evaluated in vitro as a drug carrier in 
hydrocolloids and gels (Knapczyk, 1993b; Kristl et al., 1993), and as a hydrophilic matrix 
retarding drug release in tablets (Kawashima et al., 1985; Acartürk, 1989), granules (Hou 
et al., 1985; Goskonda and Upadrashta, 1993) and microparticles (Thanoo et al., 1992; 
Chandy and Sharma, 1993; Kas, 1997). The hydrophilic nature of chitosan has also 
aroused interest in its use in immediate-release formulations, e.g. as a disintegrant in small 
amounts in tablets, where it has been found to have effects similar to or better than those of 
microcrystalline cellulose (Sawayanagi et al., 1982a,b; Ritthidej et al., 1994), and as an 
excipient to increase the rate of dissolution of poorly soluble drug substances (Shiraishi et 
al., 1990; Acartürk et al., 1993; Portero et al., 1998).  
6One area in which interest is growing is use of chitosan as a bioadhesive material. 
Many commercially available chitosans exhibit fairly good mucoadhesive properties in 
vitro (Lehr et al., 1992), and interest in use of chitosan to prepare mucoadhesive systems 
has therefore been aroused. It has been suggested that times of residence of formulations at 
sites of drug action or absorption could be prolonged through use of chitosan. It has also 
been suggested that chitosan might be valuable for delivery of drugs to specific regions of 
the gastrointestinal tract, e.g. the stomach (Gåserød et al., 1998; Remuñan-López et al., 
2000), small intestine (Lehr et al., 1992; He et al., 1998; Shimoda et al., 2001), and buccal 
mucosa (Miyazaki et al., 1995; Remuñan-López et al., 1998). Delivery to other mucosal 
surfaces, e.g. delivery of peptide drugs on to the nasal epithelia has also been studied 
(Illum et al., 1994; 2002; Aspden et al., 1997; Tengamnuay et al., 2000). 
Table 1. Pharmaceutical applications of chitosan investigated. 
Application Reference  
• Diluent in direct compression of tablets Sawayanagi et al., 1982a,b; Knapczyk, 
1993a 
• Binder in wet granulation Upadrashta et al., 1992; Tapia et al., 1993; 
Henriksen et al., 1993 
• Slow-release of drugs from tablets and granules Kawashima et al., 1985; Hou et al., 1985; 
Acartürk, 1989 
• Drug carrier in microparticle systems  Thanoo et al., 1992; Chandy and Sharma, 
1993; Okhamafe et al., 1996 
• Films controlling drug release Remuñan-López and Bodmeier, 1997; 
Senel et al., 2000 
• Preparation of hydrogels, agent for increasing 
viscosity in solutions 
Knapczyk, 1993b; Kristl et al., 1993; 
Khalid et al., 1999 
• Wetting agent, and improvement of dissolution               
of poorly soluble drug substances 
Shiraishi et al., 1990; Acartürk et al., 1993; 
Genta et al., 1995 
• Disintegrant Sawayanagi et al., 1982a,b; Ritthidej et al., 
1994 
• Bioadhesive polymer Lehr et al., 1992; Miyazaki et al., 1995; 
Bernkop-Schnürch et al., 1998 
• Site-specific drug delivery (e.g. to the stomach         
or colon) 
Tozaki et al., 1997; 1999; 2002; Shah et al., 
1999; Remuñan-López et al., 2000  
• Absorption enhancer (e.g. for nasal or oral drug 
delivery) 
Illum et al., 1994; Schipper et al., 1996; 
1997; 1999; Kotzé et al., 1997 
• Biodegradable polymer (implants, microparticles) Song et al., 1996; Jameela et al., 1998 
• Carrier in relation to vaccine delivery or gene 
therapy 
Lee et al., 1998; Aral et al., 2000; 
Van der Lubben et al., 2001a,b  
7The potential value of chitosan as a novel excipient which could find extensive 
application in pharmaceutical products has been highlighted in several reports, and in 
numerous review articles relating to the field (Li et al., 1992; Illum, 1998; Dodane and 
Vilivalam, 1998; Felt et al., 1998; Paul and Sharma, 2000; Singla and Chawla, 2001). 
Despite the substantial research relating to chitosan that has been carried out in recent 
decades, many questions remain unanswered. More information is needed about the effect 
of chitosan grade on the properties of pharmaceutical formulations. The fact that 
commercially available chitosan is not always well characterized has limited use of 
chitosan (Felt et al., 1998). Comparison of results obtained by different research groups 
has been difficult because the properties of the chitosans studied, e.g. degree of 
deacetylation and/or molecular weight, have not been specified. However, in recent years 
attention has been paid producing chitosans with particular physicochemical properties, 
and desired combinations of DD and Mw. The progress made has allowed studies in which 
the effect of altering chitosan grade on the properties of pharmaceutical formulations could 
be determined. Another important issue is the in vivo behaviour of chitosan-based 
formulations. A major deficiency of studies in this field is that many have determined the 
properties of the chitosan-based formulations solely by means of in vitro methods. 
Information on the in vivo behaviour of the formulations, especially in human beings, has 
been lacking. Results of in vivo studies would reveal the value or otherwise of chitosan as 
a pharmaceutical excipient, and allow products containing chitosan to be marketed. 
1.2. In vitro characterization of specific effects of chitosan 
1.2.1. Effects of gel-forming chitosan on drug release 
Mechanism of action. Chitosan formulations can easily be prepared using conventional 
tableting or granulating methods. The simplest way of achieving slow release of drugs by 
means of chitosan is to employ it as a gel-forming excipient in matrix-type formulations. 
Retardant effects of chitosan on drug release were noticed as early as the 1980s. Chitosan 
was found to decrease rates of release of drugs from tablets during dissolution tests at 
acidic and slightly acidic pH levels (Kawashima et al., 1985; Acartürk, 1989). However, 
AkbuWa (1993a), who carried out studies at higher pH levels (pH 7.4), reported that 
chitosan exhibited no slow-release properties. This finding indicated that the effects of 
chitosan depend on the pH level. 
Mi et al. (1997) studied the mechanism of action of chitosan in slow-release matrix 
tablets in detail, and confirmed earlier findings. The formation of swellable and erodible 
chitosan gels in tablets resulted in a release mechanism typical of hydrogel-based slow-
release systems, namely non-Fickian diffusion (Ritger and Peppas, 1987b). Release 
8kinetics were almost zero-order. The results also showed that hydration of and gel 
formation by chitosan in formulations takes place more readily at acidic pH levels (pH 1.2) 
than at pH levels close to neutral (7.2). This could be explained by the cationic nature of 
chitosan. The retardant effect of chitosan on drug release was therefore found to be most 
marked in an acidic environment (pH 1.2). Gel-forming chitosan also retards drug release 
from matrix granules (Hou et al., 1985; Miyazaki et al., 1988a,b) and the effects are most 
marked in acidic environments (Goskonda and Upadrashta, 1993). 
Variables affecting release. The rate at which a drug is released from a hydrophilic 
chitosan matrix depends on the amount of chitosan involved, and on the nature of the drug. 
Increasing the amount of chitosan in tablets (Kawashima et al., 1985; Acartürk, 1989; Mi 
et al., 1997; Kristmundsdottir et al., 1995; Inoyatov et al., 1998) and granules (Miyazaki et 
al., 1988a,b) decreases release rates. Slow-release has been achieved with slightly soluble 
drug substances (Kawashima et al., 1985; Miyazaki et al., 1988a,b; Acartürk, 1989; Tapia 
et al., 1993; 2002). Formulations of readily soluble drugs have, in most cases, also 
contained excipients other than chitosan that affect release rates (Nigalaye et al., 1990; 
Adusumilli and Bolton, 1991; Kristmundsdóttir et al., 1995). AkbuWa et al. (1993b) and 
Henriksen et al. (1993) studied in detail the effects of the physicochemical properties of 
drug substances in formulations containing a chitosan salt (malate). They found that drugs 
with low solubilities in water and/or high molecular weights were released most slowly. 
The grade of chitosan has also been found to affect drug release but the effects of 
physicochemical properties of chitosan have not so far been systematically evaluated. The 
effects of altering molecular weight or degree of deacetylation have been discussed in 
some publications but no reports of studies on the effects of altering the crystallinity of 
chitosan on its ability to retard drug release are available. The effects of molecular weight 
were first evaluated using chitosan hydrocolloids. Drug release was found to be most 
effectively retarded by chitosan of high molecular weight (Kristl et al., 1993). Drug release 
rates from granules (Goskonda and Upadrashta, 1993) and tablets (Mi et al., 1997) were 
also found to decline as molecular weight increased. The effects of altering the molecular 
weight of chitosan were assessed over wide ranges (from approximately 70 kDa to         
2000 kDa) but the possible effects of degree of deacetylation were not discussed (DD was 
not specified). The effect of the increase in molecular weight was considered to be based 
on increase in viscosity of the gels formed by chitosan.  
Sabnis et al. (1997) determined the effects of altering the degree of deacetylation of 
chitosan (DD 74, 87 and 92%). They found that drug release rates from tablets decreased 
as degree of deacetylation increased, in dissolution tests at pH 1.2. It was concluded that 
the rate of uptake of solvent by the polymer matrix increased as the number of ionizable 
amino groups in the chitosan increased (i.e. as DD increased), resulting in increasing 
formation of a chitosan gel barrier. Sabnis et al. (1997) also suggested that release might 
9also have been retarded by the formation of complexes between positively charged 
chitosan and the negatively charged drug studied, diclofenac. The formulations contained 
depolymerized chitosans of low molecular weight (approximately 20 kDa). Further studies 
by the same group indicated that chitosans of low molecular weight (Mw << 100 kDa) are 
particularly liable to interact, because of easy accessibility to amino groups (Rege et al., 
1999; Sabnis and Block, 2000). 
Cross-linking treatment. Drug release from chitosan-based formulations can often be 
modified by cross-linking treatment of chitosan. Drug release from microparticles (Thanoo 
et al., 1992; Orienti et al., 1996), and various in vitro properties of chitosan hydrogels, e.g. 
swelling of the gels and gel viscosity (Guan et al., 1996; Yao et al., 1998; Khalid et al., 
1999), can be controlled by cross-linking of chitosan. During preparation of such systems 
the chitosan is treated with reagents that cause formation of networks involving covalent or 
ionic bonds. Systems of these kinds are swellable in aqueous environment and have 
properties that depend on the density of cross-linking and the reagent used. One advantage 
of this method is that it enhances the retardant effects of chitosan (Ganza-González et al., 
1999). However, the method necessitates use of reagents that can have harmful effects in 
vivo. Toxic effects have, e.g., been noted with glutaraldehyde, an agent commonly used to 
induce cross-linking (Carreño-Gómez and Duncan, 1997). 
1.2.2. Mucoadhesive effects of chitosan 
Mechanism of action. Many hydrophilic polymers adhere to mucosal surfaces as they 
attract water from the mucus gel layer adherent to the epithelial surface. This is the 
simplest mechanism of adhesion and has been defined as “adhesion by hydration” (Chen 
and Cyr, 1970). Various kinds of adhesive force, e.g. hydrogen bonding between the 
adherent polymer and the substrate, i.e. mucus, are involved in mucoadhesion at the 
molecular level (Peppas and Buri, 1985). 
Mucoadhesion of chitosan was first studied by Lehr et al. (1992), who reported that 
many commercially available chitosans adhere fairly strongly in vitro. In the studies of 
Lehr et al., forces required to detach chitosan films were measured in isolated porcine 
intestinal preparations. One important finding during the studies was that the adhesive 
properties of chitosans persisted well during repeated contacts of chitosan and the 
substrate, with the chitosan in a swollen state. It was suggested that not only adhesion by 
hydration was involved but also additional mechanisms, such as hydrogen bonding and 
ionic interactions. Important mechanism of action was suggested to be ionic interactions 
between positively charged amino groups in chitosan and the negatively charged mucus 
gel layer. In further studies, interactions between chitosan and mucus were demonstrated 
(Fiebrig et al., 1995; He et al., 1998), and the primary mechanism of action at the 
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molecular level was found to be electrostatic (Deacon et al., 2000). It has also been shown 
that adsorption of hydrophilic chitosan on mucosal surfaces and mucosal dehydration are 
involved in the adhesion of chitosan (Patel et al., 1999; 2000). 
Variables affecting mucoadhesion. Interactions of chitosan with mucus and its 
mucoadhesive properties are affected by both physiological factors and the properties of 
chitosan. The principal component of mucus is mucous glycoprotein, or mucin, which 
contains negatively charged residues, e.g. sialic acid in gastric mucin (Allen, 1978). 
Chitosan adsorbs mucin. The extent of adsorption increases with the amount of sialic acid 
in the mucin (He et al., 1998). Deacon et al. (1999) showed that interactions are more 
marked with mucins from the cardiac region of the porcine stomach than from the corpus 
or antrum. This finding could be explained by the fact that amounts of sialic acid in 
secretions from the cardiac region are high (Nordman et al., 1997). Because amounts of 
sialic acid in mucosal secretions vary, the strength with which chitosan adheres to mucus 
may differ between tissues. Since the mechanism of adhesion also involves electrostatic 
interactions pH is also important. Interactions are strong at acidic and slightly acidic pH 
levels, at which the charge density of chitosan is high (He et al., 1998). Accordingly, 
microspheres coated with chitosan adhered to isolated porcine gastric mucosa in simulated 
gastric fluid (pH ~1.2), but adhesion to oesophagus moistened with artificial saliva (pH ~7) 
was less strong (Gåserød et al., 1998).  
The molecular weight and charge of chitosan are important properties in relation to           
its capacity for mucoadhesion. Increase in molecular weight of chitosan results in stronger 
adhesion (Lehr et al., 1992). This would be expected, because penetration of polymer 
chains into the mucus layer should become more efficient as the chain length of the 
polymer increases (Peppas and Buri, 1985). He et al. (1998) reported that an increase in the 
charge density of chitosan results in adhesive properties becoming more marked. The 
charge density of a chitosan in a formulation is affected by its degree of deacetylation and 
any cross-linking treatment. Using rat-gut-loop preparations, He’s research group showed 
that amounts of chitosan microspheres adhering to the intestine were greatest when the 
density of cross-linking of chitosan was least, i.e. when the number of free amino groups in 
chitosan was greatest. This finding suggests that the adhesive properties of chitosan should 
become more marked as degree of deacetylation increases. It is also obvious from the 
results that cross-linking procedures should be avoided when formulations for 
mucoadhesive drug delivery are being developed. Results of other studies have also 
indicated that cross-linking reduces mucoadhesive effects of chitosan (Bernkop-Schnürch 
et al., 1998; Genta et al., 1999). 
Like other hydrophilic mucoadhesive polymers, chitosan adheres most readily when 
the degree of hydration is optimal. In the study of Gåserød et al. (1998) adhesive 
tendencies of chitosan formulations decreased markedly when they were hydrated in 
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simulated gastric fluid with mucin for longer than 15 minutes before tissue contact 
(isolated porcine gastric mucosa). 
Novel effects of mucoadhesives. There is currently a search for mucoadhesive 
polymers that are multifunctional, e.g. polymers that can also temporarily increase 
epithelial permeability (Lehr, 1996; Lee et al., 2000). Such polymers are intended for 
particular purposes, e.g. enhancement of the absorption of peptide drugs. The low 
solubilities of chitosan bases and also many chitosan salts make them unsuitable for use in 
such applications but soluble chitosan derivatives (e.g. N-trimethylchitosan chloride) have 
been found to show promise as absorption enhancers. They dissolve readily over a wide 
pH range and then increase epithelial permeability in vitro by opening the intercellular 
junctions of epithelial cells (Kotzé et al., 1997; 1998; 1999; Thanou et al., 1999). Studies 
characterizing the in vitro mucoadhesive properties of such chitosan derivatives are in 
progress (Snyman et al., 2003). 
1.3. Mucoadhesive chitosan in slow-release formulations for 
gastro-retentive drug delivery 
1.3.1. Special properties of chitosan 
Even in early publications it was suggested that chitosan could be of particular value for 
controlling drug release from oral dosage forms (Hou et al., 1985). More recently, it has 
been suggested that chitosan formulations could also be used for gastro-retentive drug 
delivery (Shah et al., 1999; Remuñan-López et al., 2000; Hejazi and Amiji, 2002). Two 
properties in particular make chitosan potentially valuable in such dosage forms, namely 
its ability to form gels that control drug release at acidic pH levels, and its mucoadhesive 
properties. Both properties are closely related to the cationic nature of chitosan. 
Chitosan could be ideal for use in formulations intended to release drugs slowly in 
the stomach, since the gel formation by cationic chitosan that is pronounced at acidic pH 
levels results in marked retardant effects on drug release (Section 1.2.1.). Orally 
administered formulations are initially exposed to the acidic milieu of the stomach, 
especially if they have been administered to subjects in fasted states, in whom gastric pH is 
likely to range from approximately 1 to 2. Polymers commonly used in preparing slow-
release formulations do not form gels very efficiently in such environments. For example, 
with hydroxypropylmethylcellulose (HPMC), which is non-ionic, stable gels are formed 
within the pH range 3–11 (Alderman, 1984). Anionic polymers may even require pH 
values to be close to neutral before they will form gels. Gel formation by chitosan, in 
contrast, takes place readily at acidic pH levels, because of its cationic character. 
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Mucoadhesive effects of chitosan (Section 1.2.2.) are interesting. Hydrated chitosan 
has a positive charge and can adhere to negatively charged mucus gel layers, as results of 
studies e.g. on isolated porcine gastric mucosa preparations have shown (Gåserød et al., 
1998). This ability could result in formulations containing chitosan being retained in the 
stomach. Adhesion would be expected to be particularly marked under the acidic 
conditions in the stomach, where cationic chitosan would be highly charged. Other 
mucoadhesive polymers are most commonly anionic (e.g. acrylic acid co-polymers) or 
non-ionic (e.g. cellulose derivatives) (Lee et al., 2000). With such polymers adhesion could 
take place via hydrogen bonding between the polymer and substrate. Although this 
mechanism could also be involved in relation to chitosan, the positive charge of the latter 
could result in there being additional forces of attraction (Lehr et al., 1992). 
It is rare for polymers used as pharmaceutical excipients to have cationic nature. The 
effects of chitosan are therefore quite unique. It is, consequently, not surprising that there 
has been increasing interest in use of chitosan to prepare slow-release formulations for 
gastro-retentive drug delivery. It has been suggested that such dosage forms could be 
valuable, e.g., in relation to administration of antibiotics intended to eradicate Helicobacter 
pylori (Shah et al., 1999; Remuñan-López et al., 2000). They could also be useful for 
administration of drug substances that are site-specifically absorbed from the upper 
gastrointestinal tract or degraded in the intestine. A slow-release formulation that was 
retained for a time in the stomach could increase the bioavailability of such substances. 
There are already patents relating to various kinds of chitosan systems intended to release 
drugs slowly in the stomach, e.g. microspheres (Japanese Pat. JP1224311, 1989; Japanese 
Pat. JP5017371, 1993), and cross-linked gels (United States Pat. US5620706, 1997; United 
States Pat. US5904927, 1999). Most such patents are based on results of in vitro studies. 
However, de la Mata et al. (European Pat. Application EP1238663 A2, 2002) have shown 
that floating chitosan gel mixtures are being retained in the stomachs of pigs and are 
therefore potentially valuable as gastro-retentive drug delivery systems. 
1.3.2. In vivo behaviour of chitosan formulations; unanswered questions 
So far, surprisingly little information has been published on the in vivo behaviour of 
chitosan formulations, especially in human beings. Information is needed on both the slow-
release characteristics of chitosan formulations and their mucoadhesive properties. 
Evidence relating to slow release in vivo. Attempts have been made to confirm the 
value of chitosan systems in animals. Miyazaki et al. (1988a,b) were among the first to 
carry out experiments in vivo on slow-release characteristics of chitosan formulations. 
Using a small-scale extrusion method, they prepared chitosan matrix granules, release of 
drug from which was thought to be controlled by formation of chitosan gels. Release of 
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indomethacin from the granules in vitro was slow, and the granules also seemed to behave 
as slow-release formulations in rabbits (Miyazaki et al., 1988a) and beagle dogs (Miyazaki 
et al., 1988b). However, there were only three animals in each study, and the results 
obtained varied considerably. Miyazaki et al. were unable to demonstrate statistically 
significant differences between rates of absorption (evaluated in terms of tmax) from a 
conventional capsule formulation and from chitosan granules. Inoye et al. (1988), who 
tested chitosan tablets containing prednisolone in three beagle dogs, obtained similar 
results. Larger groups would have been needed to determine whether the formulations had 
potential as slow-release dosage forms. The information obtained relating to slow-release 
properties of chitosan formulations in vivo was limited because only a few variables were 
studied. Miyazaki et al. (1988a,b) reported that high amounts of chitosan in granules 
retarded drug absorption but did not discuss effects of altering chitosan grade (neither the 
Mw or DD of the chitosan used was stated). In the study of Inoye et al. (1988) tablets 
contained chitosans with different degrees of deacetylation but a possible effect of 
molecular weight was not taken into account (DD was 93% and 50–60%, Mw was not 
stated). The tablets contained also different amounts of other excipients, making 
comparisons between the effects of the chitosans studied difficult. Bioavailability studies 
by Shiraishi et al. (1993) in beagle dogs and by Imai et al. (2000) in human volunteers 
have shown that slow-release formulations of indomethacin can be prepared using cross-
linked chitosan in granules. 
Evidence relating to mucoadhesion in vivo. Adhesion of chitosan formulations to the 
mucosa of the gastrointestinal tract has been assessed in only a few studies. Miyazaki et al. 
(1988a) may have been the first to discover evidence that gastric residence times of 
formulations could be prolonged through use of chitosan. They found that chitosan 
granules were retained in the rabbit stomach for at least three hours (results recorded for 
only one rabbit). They suggested that retention in the stomach could result from flotation 
of the granules on gastric contents, but did not raise the possibility that chitosan might have 
mucoadhesive properties. Following further studies, it has been suggested that adherence 
of chitosan to the mucosa may be the important mechanism in relation to prolonged 
residence times of chitosan-based formulations in regions of the gastrointestinal tract. 
The mucoadhesive properties of chitosan were first assessed in vitro, in isolated 
mucosal preparations. In a study by Gåserød et al. (1998) microspheres coated with 
chitosan were found to adhere to isolated porcine gastric mucosa. Chitosan has also been 
found to adhere to isolated porcine intestinal mucosa in studies in which forces required to 
detach chitosan films were measured (Lehr et al., 1992), and to rat intestine in wash-off 
studies in which percentages of chitosan microspheres that adhered to an isolated rat gut 
loop were taken as measures of the mucoadhesion of chitosan (Takeuchi et al., 1996; He et 
al., 1998; Yamamoto et al., 2000). 
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Results relating to the possible adherence of chitosan formulations in vivo have been 
published only recently. There are reports of studies of adherence of chitosan microspheres 
to murine gastric mucosa (Remuñan-López et al., 2000) and rat intestinal mucosa 
(Shimoda et al., 2001). In the studies mentioned, the stomach and small intestine of an 
anesthetized animal were excised a predetermined time after administration of 
formulations containing chitosan and a fluorecent label. Fluorecence in various regions 
was measured and taken as a measure of adherence of the formulations. In the study of 
Remuñan-López et al. (2000), chitosan microspheres were even found in the murine 
stomach four days after administration. The authors did not, however, provide information 
on the kinetics of adhesion over time, or record amounts of microspheres remaining. 
Chitosan microspheres were also found to adhere to intestinal mucosa in studies by 
Shimoda et al. (2001). Different amounts of microspheres were retained in the rat intestine 
over a period of eight hours. Although the chitosan formulations studied exhibited 
mucoadhesive properties in rodents, the authors did not discuss whether their results might 
be reproducible in human beings. It is, however, well known that extrapolation to man of 
results obtained in animal studies with formulations intended to retain in the stomach        
is subject to substantial limitations. For example, Harris et al. (1990a,b), who studied 
commonly used mucoadhesive polyacrylic-acid-based polymers, found a poor correlation 
between results in the rat and in man. Although the polymers exhibited good adhesive 
properties in the rat, adhesion was rare in human volunteers. No significant differences 
were found between gastric residence times of the polymers studied and residence time of 
a reference formulation (lactose), in gamma scintigraphic investigations in man. It has 
been concluded that the poor correlation between results obtained in studies in rodents and 
results obtained in studies in higher species (the dog, man) can be explained for the most 
part on the basis of the physiological differences between the species (Jiménez-Castellanos 
et al., 1993). The discrepancies between results obtained in animal studies and in studies in 
human volunteers show the importance of studies in man as well as in animals. 
Study results make it obvious that more information on the in vivo behaviour of 
systems containing chitosan is needed, and that there should be particular focus on study of 
chitosan formulations in human beings. Only after in vivo studies in human volunteers can 
conclusions be reached regarding the value of chitosan formulations as slow-release 
systems for gastro-retentive drug delivery. To allow optimization of the characteristics of 
chitosan-based drug delivery systems in vivo, the effects of different variables, e.g. 
chitosan content and the grade of chitosan used, on drug absorption and/or gastric 
residence times of formulations needed to be studied. The effects of the physicochemical 
properties of chitosan also required systematic evaluation, in vitro and in vivo. 
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1.4. Safety of chitosan in oral use 
The biocompatibility of chitosan has been evaluated in several studies (Arai et al., 1968; 
Muzzarelli et al., 1988; Knapczyk et al., 1989; Kim et al., 2001). Chitosan is currently 
regarded as relatively safe following oral administration. It is not specifically degraded in 
the human intestine, because chitinase and chitosanase enzymes are not present (Shahidi et 
al., 1999). It is therefore not absorbed from the intestine in significant amounts. Limited 
digestion of chitosan by enzymes produced by bacteria in the intestine may occur 
(Okamoto et al., 2001; Zhang and Neau, 2002). Results of toxicity tests in rodents have 
shown that chitosan is relatively harmless following oral administration. Administration at 
a dose of 15 g/kg in rats (Wistar), in solution or as a powder for 14 days, resulted in no 
acute toxic effects or pathological changes (Knapczyk et al., 1989). The oral LD50% of 
chitosan in mice has been reported to be over 16 g/kg (Arai et al., 1968). 
Side effects of chitosan following oral administration relate to its effects within the 
gastrointestinal tract. Consumption of several grams of chitosan daily by humans can result 
in constipation or diarrhoea, because chitosan entraps water and lipids in the intestine 
(Koide, 1998; Pittler et al., 1999). In studies in rats, long-term ingestion of high doses of 
chitosan has also led to reductions in absorption of minerals and fat-soluble vitamins, 
because of chitosan’s ability to adsorb lipids (Deuchi et al., 1995). In man, in trials lasting 
for up to 12 weeks, no clinically significant adverse effects or changes in laboratory values 
relating to safety have been noted. Chitosan treatment had no effects on serum electrolyte 
levels (Jing et al., 1997) or fat-soluble vitamin levels (Wuolijoki et al., 1999, Pittler et al., 
1999). The amounts of chitosan needed in pharmaceutical formulations are fairly low (less 
than 1000 mg/dose), and risks of side effects in the gastrointestinal tract are therefore also 
low. Although chitosan is clinically well tolerated it has been suggested that it might not be 
desirable for administration to individuals allergic to crustaceans, in whom consumption of 
crustaceans frequently results in allergic reactions, and serious adverse reactions are 
possible (Ylitalo et al., 2002). On the other hand, chitosan has been widely used in non-
medical natural products. No information about allergic reactions relating to these products 
has been available. 
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2. Study strategy 
In the studies described a highly crystalline grade of chitosan base, microcrystalline 
chitosan (MCCh) was evaluated for the first time as a pharmaceutical excipient. Studies 
intended to allow determination of properties of MCCh as excipient in granules from 
which drug release would be controlled through gel formation by the MCCh, and which 
were also expected to be mucoadhesive. A final aim was to evaluate whether MCCh 
formulations would allow slow-release of drugs in the human stomach. In addition to the 
general advantages which it has been suggested that chitosan exhibits in formulations 
administered orally (see Section 1.3.1.), MCCh could offer particular advantages, such as 
efficient gel formation in formulations and marked retarding effects on drug release. 
2.1. Choice of microcrystalline chitosan and study variables 
In previous studies of pharmaceutical formulations little attention has been paid to the 
effects of the crystallinity of chitosan. Most studies were carried out using chitosans 
produced commercially, using conventional methods. Chitosans of this kind are fairly 
amorphous, as indicated by powder X-ray diffraction patterns (Struszczyk, 1987; Genta et 
al., 1995; Portero et al., 1998; Mura et al., 2003). MCCh differs from conventional 
chitosan in respect of greater crystallinity, energy of hydrogen bonds, and water retention 
(Struszczyk, 1987). Both high energy of hydrogen bonds and high water retention are 
properties reflecting the increase in crystallinity and the substantial surface area of MCCh. 
The ability of MCCh to retain high amounts of water is a property which could be of 
particular value in relation to slow-release formulations. MCCh can retain three to four 
times as much water as the parent chitosan (Struszczyk, 1987). This might result in MCCh 
having a greater capacity than conventional chitosan to form gels in formulations, and 
result in marked retardant effects on drug release. 
Mucoadhesive tendency of chitosan might also depend on its crystallinity. Efficient 
gel formation by MCCh could result in substantial mucoadhesion, at least as far as 
“adhesion by hydration” is concerned. Results of studies relating to technical applications 
of chitosan have indicated that the reactivity of MCCh is greater than that of conventional 
chitosan, because of the greater ability of MCCh to form hydrogen bonds (Struszczyk and 
Kivekäs, 1992). Because adhesion of chitosan to mucosa takes primarily through hydrogen 
bonding and electrostatic interactions, differences in ability to form hydrogen bonds might 
be reflected in differences in capacity to adhere to mucosa. 
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All of the properties of MCCh mentioned suggest that it might be used to prepare 
slow-release and mucoadhesive formulations better than those that can be made using 
conventional chitosan. It was obvious that the effects of use of MCCh needed to be 
determined and compared with those seen when conventional chitosan was used. Results 
of previous in vitro studies relating to conventional chitosan suggested that both drug 
release from (see Section 1.2.1.) and mucoadhesive properties of (see Section 1.2.2.) 
chitosan formulations could be affected by altering the molecular weight and degree of 
deacetylation of chitosan. In the studies described it therefore seemed reasonable in the 
first place to determine the effects of physicochemical properties of chitosan, including the 
effects of differences in crystallinity (MCCh versus conventional chitosan), and the effects 
of differences in molecular weight (Mw) and degree of deacetylation (DD) of MCCh.   
Other formulation variables that could affect drug release (see Section 1.2.1.) and thus also 
require evaluation in MCCh formulations were the amount of MCCh used, and the drug 
substance concerned. 
2.2. Choice of study methods 
2.2.1. In vitro studies 
Studies in vitro in standardized environments are fundamental for characterization of 
effects of formulation-related factors on the properties of a drug delivery system. The basic 
idea behind the studies described here was to develop MCCh granules from which drug 
release could be controlled through formation of gels, and which were also expected to be 
mucoadhesive. To allow the in vivo behaviour of such formulations to be understood and 
controlled, the effects of the study variables mentioned in section 2.1. needed to be 
evaluated first in vitro, concentrating on gel formation by MCCh in granules, drug release 
from granules, and mucoadhesive tendency. 
Gel formation studies. Studies relating to gel formation were needed in the first place 
to determine whether there were differences in relation to gel formation between MCCh 
and conventional chitosan. Conduct of such studies was justified particularly by the fact 
that the ability of a hydrophilic polymer to form gels is usually related to its retardant 
effects on drug release (Alderman, 1984). Simple methods of determining capacity for gel 
formation are measurement of increase in weight of a formulation during hydration 
(gravimetry) and observation of swelling of a formulation (swelling method). Granules can 
be studied using the latter method. 
Dissolution tests. The potential of MCCh as an excipient to modify drug release rates 
can be assessed by means of dissolution tests on formulations containing different amounts 
of MCCh and incorporation of model drugs that differ in their solubilities in water at 
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physiological pH levels. Paracetamol was chosen as a representative of drug substances 
readily soluble throughout the physiological pH range (a Class-I drug in the 
Biopharmaceutics Classification System (BCS)) (Amidon et al., 1995). Ibuprofen (a BSC 
Class-II drug) and furosemide (a BCS Class-IV drug) were, in contrast, representative of 
drug substances slightly soluble in acidic environment. Ibuprofen and furosemide differ in 
their in vivo absorption characteristics. These differences are discussed in detail in       
Section 2.2.2. (In vivo studies). 
Mucoadhesion tests. In vitro tests were also needed to determine mucoadhesive 
tendency of MCCh. Several methods currently exist for determining the mucoadhesive 
tendencies of pharmaceutical excipients in vitro (Peppas et al., 2000). One common 
method is measurement of detachment force. The potentially mucoadhesive polymer is 
brought in contact with an isolated mucosal preparation for a predetermined time, and the 
force required to separate the material from the tissue is then measured. This result can be 
used as a measure of adhesion. This method has been very popular for decades, perhaps 
because it is simple and quick. An example of this type of method is the isolated porcine 
oesophagus preparation developed by Marvola et al. (1982; 1983). This method has turned 
out to be useful for evaluating the adhesive tendencies of different kinds of pharmaceutical 
materials, and it was felt that it would also be useful in studies of chitosan. In particular, it 
was anticipated that results obtained using the method would not represent overestimates 
of the likely value of the chitosan grades studied in relation to preparation of dosage forms 
for gastro-retentive drug delivery. Adhesion of chitosan to gastric mucosa in vivo may be 
greater than adhesion to the oesophageal tissue, because in the stomach pH levels are 
highly acidic and the mucus gel layer is thick, with a high charge density (Gåserød et al., 
1998). The oesophagus contains rather small amount of mucus, pH of which is about 5 to 
6. Because the aim of the studies described was to develop MCCh formulations that would 
be gastro-retentive, it was felt to be desirable to immerse formulations in simulated gastric 
fluid (pH ~1.2) before adhesion testing, to enhance gel formation by chitosan. 
2.2.2. In vivo studies 
Conditions in all commonly used in vitro methods differ markedly from conditions in vivo. 
Data from in vitro studies, and even data from animal studies, often fail to predict the fate 
of a formulation in man (Davis and Wilding, 2000). This has led to the conclusion being 
drawn that in many cases “the best model for man is man” (Newman et al., 2003). Since 
there was little evidence that chitosan formulations behave as intended in vivo (see Section 
1.3.2.), the focus of studies described here was on evaluation of the characteristics of 
MCCh formulations in human volunteers. In vivo study methods that could demonstrate 
whether MCCh granules had potential as slow-release formulations for gastro-retentive 
19
drug delivery were needed. Bioavailability studies and gamma scintigraphic investigations 
were felt to be appropriate for these purposes. To overcome the limitations that very 
commonly apply when data from animal studies is extrapolated to human situations, 
studies were carried out in volunteers. 
Bioavailability studies. The slow-release characteristics of MCCh granules can be 
evaluated by means of bioavailability studies. Such studies were needed to determine 
whether granules from which drug release was slow could be formulated using MCCh, and 
whether the slow-release characteristics of such granules in vivo could be controlled by 
altering variables such as the grade or amount of MCCh. The choice of model drug to be 
incorporated in the formulations investigated was important. Initially it was felt appropriate 
to carry out the studies using ibuprofen, for two reasons. Firstly, ibuprofen is readily 
absorbed throughout the gastrointestinal tract (Wilson et al., 1989). Secondly, it has a short 
elimination half-life (t½ ~2 h). It was assumed that the short elimination half-life would 
facilitate investigation of the effects of altering formulation variables on absorption rate, 
since a decrease in drug release rate would rapidly be reflected in the length of the 
elimination phase. Subsequently, furosemide was also used. The bioavailability studies 
with furosemide formulations were intended in particular to provide indirect information 
on the gastro-retentive properties of MCCh formulations. Absorption of furosemide is 
strongly site-specific, and takes place in the stomach and upper parts of the small intestine 
(Staib et al., 1989). If a slow-release MCCh formulation is gastro-retentive, the tmax value 
for furosemide should be higher and the Cmax value lower than with a conventional 
furosemide formulation, while the AUC0- value should be similar to or higher than that of 
a conventional formulation. If, in contrast, a slow-release formulation is not retained in the 
stomach, both AUC0- and Cmax values should decrease, because most of the furosemide 
passes the sites of absorption in the upper gastrointestinal tract before being released from 
the formulation. 
Gamma scintigraphy. Results of gamma scintigraphic studies can be used to draw 
conclusions on the value of MCCh in preparing gastro-retentive formulations. Gamma 
scintigraphy is currently regarded as the best imaging technique for obtaining data on the 
fate of a formulation in the gastrointestinal tract by non-invasive means (Wilding et al., 
2001; Newman et al., 2003). The greatest advantage of the method over radiological 
studies that have been widely used is that it allows visualization over time of the entire 
course of transit of a formulation through the gastrointestinal tract, with reasonably low 
exposure of subjects to radiation. In X-ray studies the data obtained are inevitably limited 
because to conduct serial X-rays would expose subjects, e.g. healthy volunteers, to high 
doses of radiation. 
Gamma scintigraphy based on neutron activation has proved to be a particularly 
good method for study of modified-release drug delivery systems (Wilson, 1998; Wilding 
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et al., 2001). It was felt it would be appropriate for determining whether MCCh 
formulations were gastro-retentive. The method involves labelling the formulation studied 
with a nuclide emitting gamma radiation, allowing subsequent imaging of the formulation 
in the gastrointestinal tract by means of an external gamma camera. A stable isotope (in 
this case 152samarium) is incorporated in the formulation during manufacture, and activated 
in a neutron flux to a radioactive isotope (in this case 153samarium, t½ 46.3 hours) before 
the in vivo studies. There are several advantages of the neutron activation method over 
other radio-labelling techniques used in gamma scintigraphy. In particular, handling of 
radioactive isotopes during manufacture is avoided (Digenis and Sandefer, 1991). Other 
gamma scintigraphic techniques most commonly involve use of 99mtechnetium, which is 
radioactive during manufacture of the drug products concerned. A short half-life of the 
label (for 99mTc it is 6 hours) could also result in problems. 
A drawback of neutron activation is that it can alter the in vitro and in vivo 
properties of a formulation. Irradiation can result in degradation of polymeric excipients, 
e.g. of hydroxypropylmethylcelluloses (HPMC), resulting in decreases in polymer gel 
viscosities and consequent faster drug release from formulations containing the polymer 
(Ahrabi et al., 1999; 2000). Before gamma scintigraphic studies effects of neutron 
activation on MCCh therefore needed to be determined. Because it was anticipated that 
any changes in polymer structure would be reflected in the properties of gels formed by the 
polymer, as had been shown in previous studies, in vitro quality control studies, in 
particular swelling and dissolution studies, were needed to demonstrate that neutron 
activation process had had no effect on the MCCh. Only MCCh grades the properties of 
which do not change markedly during irradiation can be used in the in vivo tests intended 
to reveal whether formulations containing MCCh are gastro-retentive. 
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3. Aims of study 
The first objective of this study was to determine the properties of MCCh, a highly 
crystalline grade of chitosan base, as an excipient that would form gels and control the 
release rate of drugs, and which was also expected to be mucoadhesive. The properties of 
MCCh were compared with those of conventional chitosan, which is predominantly 
amorphous. The effects of altering the molecular weight and degree of deacetylation of 
MCCh were also studied. 
The ultimate objective of the study was to evaluate whether MCCh granules had 
potential as slow-release systems for gastro-retentive drug delivery. The basic idea was 
that a gel that controlled drug release would form readily in the stomach from the cationic 
chitosan used to construct a hydrophilic matrix in the granules. Because hydrated chitosan 
has been found in several in vitro studies to be mucoadhesive, it was expected that it would 
adhere to the gastric mucosa and thus make the formulation gastro-retentive. 
 
In detail, the aims of the study were:  
1. To determine in vitro whether gel formation by chitosan in granules is affected by 
the crystallinity of chitosan, by comparing formulations made using MCCh with 
formulations made using conventional chitosan, and to determine the effects of 
altering the crystallinity, molecular weight and degree of deacetylation on drug 
release from and the mucoadhesive characteristics of chitosan formulations. 
2. To determine in vitro how model drugs (paracetamol, ibuprofen and furosemide) 
with different aqueous solubilities at physiological pH levels behaved in MCCh 
granules, and to evaluate the potential of granules containing different amounts of 
MCCh as slow-release systems for these drugs. 
3. To determine, by means of bioavailability tests in human volunteers, how drug 
absorption is controlled by MCCh in granule formulations, by using in the 
formulations a drug substance that is readily absorbed throughout the gastro-
intestinal tract (ibuprofen) and one absorbed only in the upper regions of the 
gastrointestinal tract (furosemide). 
4. To determine, by means of gamma scintigraphic investigations, whether MCCh 
formulations have gastro-retentive properties in human volunteers. 
22
4. Materials and methods 
4.1. Chitosans 
The characteristics of microcrystalline chitosan (MCCh) as polymer capable of forming 
gels that might control drug release, and likely to possess mucoadhesive properties were 
evaluated. MCCh (Novasso Ltd, Finland) differing in extents of deacetylation (DD) and 
molecular weights (Mw), and conventional chitosan (Ch) (Primex Ingredients ASA, 
Norway) were employed. The chitosans studied and their properties, as reported by the 
supplier, are shown in Table 2.  
Table 2. Chitosans studied. MCCh, microcrystalline chitosan; Ch, conventional chitosan; 
DD, approximate degree of deacetylation; Mw, approximate molecular weight a.
Quality DD (%) Mw (kDa) 
MCCh A 75   25 
MCCh B 75 150 
MCCh C 75 240 
MCCh D 90 120 
Ch E 90 160 
a Range of variation in Mw ± 20 – 30 kDa 
MCCh was manufactured from conventional chitosan in accordance with 
specifications (Struszczyk, 1987) using a continuous method (Finnish Pat. FI83426, 1991). 
The crystallinity of MCCh manufactured using this method is up to 30% higher than that 
of conventional chitosan. Chitosan of grade A was representative of a low-Mw chitosan, 
and grades B, C, D and E of high-Mw chitosans (Table 2). Grades A, B and C had low DD,
grades D and E high DD. All of the chitosans studied were in the form of the base. Studies 
were initially carried out using chitosan of grades A, B, D and E to prepare the 
formulations concerned. Following a request by us, the MCCh supplier provided MCCh    
of grade C from study III on.  
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4.2. Model drugs  
Model drugs (paracetamol, ibuprofen and furosemide (Ph.Eur.)) that differ in their aqueous 
solubilities and in their absorption characteristics were incorporated in the formulations. 
In the in vitro studies the weak acids paracetamol (pKa 9.5, Mw 151.2 g mol-1) (I), 
which is readily soluble in water throughout the physiological pH range, and ibuprofen 
(pKa 5.3, Mw 206.3 g mol-1) (I and II) and furosemide (pKa 3.9, Mw 330.7 g mol-1) (II–IV), 
which are sparingly soluble in acidic aqueous solutions, were used. 
In the bioavailability studies ibuprofen (II), which is readily absorbed throughout the 
gastrointestinal tract (Wilson et al., 1989), and furosemide (II and III), which is site-
specifically absorbed only in the upper regions of the gastrointestinal tract (Staib et al., 
1989), were used. Both drugs have short elimination half-lives (t½). Values reported are      
2 ± 0.5 hours for ibuprofen and 0.5 to 2 hours for furosemide (Handbook of Clinical Drug 
Data, 1993).  
4.3. Study formulations 
The studies were carried out using chitosan matrix granules (I–V), except in the case of the 
in vitro mucoadhesion studies, in which the chitosans were compressed into tablets (III). In 
preliminary tests (I) dilute chitosan gels were studied. Detailed descriptions of the 
compositions and preparation of the formulations are given in the original publications (I–
V). Conventional granulating and tableting methods were used.  
Granules. Percentages of chitosan in granules varied from 5 to 95 (I–V). In study II, 
enteric polymers insoluble at gastric pH levels were incorporated in the granule matrices 
(0, 2.5, 5 and 10%, Eudragit S100®, Röhm Pharma, Germany) or used as coatings (0, 5, 
10 and 20%, Aqoat AS-HF®, Shin-Etsu Chemical Co., Japan) to determine whether they 
could be used to reinforce the gels formed by MCCh, and control drug release at acidic pH 
levels. In study III an organic acid was added to the formulation (0, 2.5, 5 and 10% of 
tartaric or citric acid (Ph.Eur.)), to determine whether doing so enhanced gel formation by 
MCCh, and prolonged drug release. In the gamma scintigraphic studies (IV and V) natural-
abundance samarium oxide (Sm2O3) (Aldrich, USA) was used as radio-label in the 
granules. Lactose (Pharmatose DCL 21, DMV International, Netherlands) granules which 
contained polyvinylpyrrolidone (PVP K25, Fluka Chemie, Switzerland) as binder were 
used as reference formulation. 
Tablets. The chitosan tablets used in the in vitro adhesion studies (III) contained only 
chitosan and 1% of magnesium stearate (Ph.Eur.). The reference tablets were enteric-
coated (Eudragit S100®, Röhm Pharma, Germany) tablets of microcrystalline cellulose 
(Emcocel LP 200, Mendell, USA). 
24
4.4. In vitro studies 
4.4.1. Properties of chitosan gels (I) 
The effect of grade of chitosan on the properties of gels formed was first studied, at various 
chitosan concentrations (1, 2 and 4%). The gels were prepared in slightly and markedly 
acidic aqueous solutions. Gel pH levels (InLab412 combination electrode, Mettler Toledo, 
Switzerland) and apparent single viscosity values (DV-II Brookfield digital viscometer, 
Brookfield Engineering Laboratories, USA) were determined at room temperature. 
4.4.2. Gel formation by chitosan in granules (I, IV) 
The effect of grade of chitosan on gel formation by chitosan in granules (I) was studied by 
means of light microscopy (Leica DMLB 020-519.511, Leica Mikroskopie und Systeme, 
Germany). Increases in granule diameters were measured over time, under markedly     
(pH 1.2 and 2.2) and slightly (pH 5.8) acidic pH conditions. Gel formation was also 
studied (at pH 1.2) when determining the effects of neutron activation on MCCh (IV). 
4.4.3. Drug release from chitosan granules (I–IV) 
The effects on drug release of grade of chitosan, amount of chitosan used, and other 
excipients in the granules were studied by means of dissolution tests (Apparatus Distek 
Premiere 5100, Distek, USA), using the basket method (USP 24). The dissolution media 
used were phosphate buffer pH 5.8 (1000 ml, 37 ± 0.5oC) for granules containing the 
slightly soluble acidic drugs ibuprofen and furosemide, and hydrochloric acid buffer        
pH 1.2 and phosphate buffer pH 5.8 (500 ml, 37 ± 0.5oC) for granules containing 
paracetamol, which is readily soluble. In studies III and IV, with furosemide as model 
drug, granules were pre-treated at pH 1.2 (in 7.5 ml of buffer) for one hour, to simulate pH 
conditions in the stomach, before dissolution tests were conducted at pH 5.8. Speeds of 
rotation in tests were 100 min-1 (ibuprofen, furosemide) and 50 min-1 (paracetamol). 
Amounts of drug released were determined spectrophotometrically (Ultrospec 4000, 
Pharmacia Biotech, UK). Dissolution tests were also carried out when determining the 
effect of neutron activation on MCCh (IV). 
Drug-release kinetics (I) were evaluated using the empirical equation Mt/M = ktn
describing fractional release from swellable devices (Ritger and Peppas, 1987a,b). In this 
equation, Mt/M is the fractional amount of drug released at time t, k is the kinetic constant 
and n is an exponent indicative of the diffusional mechanism of release. The exponent n
has limit values that depend on the geometry of the device, which indicate whether 
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diffusion-controlled Fickian release is taking place. Greater values of n indicate non-
Fickian release. In such a case drug release depends on the ratio between polymer 
relaxation rate and rate of diffusion of drug in gel. 
4.4.4. In vitro mucoadhesion of chitosan (III) 
The effect of grade of chitosan on its mucoadhesive tendency was studied using the 
isolated porcine oesophagus preparation described by Marvola et al. (1982; 1983). Tablets 
containing various grades of chitosan were first moistened in simulated gastric fluid      
(pH ~1.2) without enzymes (USP 24) and then placed on an oesophageal preparation. The 
shear force needed to detach the tablet from the preparation was taken as a measure of the 
mucoadhesive tendency of the grade of chitosan concerned. Enteric-coated (Eudragit 
S100®, Röhm Pharma, Germany) tablets were used as reference formulations in the 
studies because the enteric coating was expected to exhibit only a slight tendency to adhere 
to the isolated porcine oesophagus. 
4.5. In vivo studies 
4.5.1. Bioavailability studies (II–III) 
Six groups of eight or nine healthy volunteers participated in a series of randomized, 
crossover single-dose studies. Each volunteer had given informed consent in writing to 
participation in the studies. The investigations were carried out in accordance with the 
recommendations of the Declaration of Helsinki (World Medical Assembly, 1964) as 
revised in Edinburgh in 2000. The study protocol had been approved by the Ethics 
Committee of the University Hospital of Tartu. 
Procedure. Compositions of the formulations studied are described in Table 3. The 
amounts of ibuprofen and furosemide administered in the study were 300 mg (II), and     
40 mg (II and III), respectively. Granules dispensed in size-0 gelatine capsules (Ph.Eur.) 
were administered to each subject with 200 ml of water, after the subject had fasted 
overnight for at least 10 hours. Lunch was provided four hours after drug administration. 
Venous blood samples were collected at intervals. The washout period between 
administration of different formulations was at least one week. 
Assay methods. Drug concentrations in plasma were determined by means of high-
performance liquid chromatography (HPLC). Methods described by Avgerinos and Hutt 
(1986) and Beermann (1982) were used, with slight modifications, for ibuprofen and 
furosemide determinations, respectively. Accuracy and precision of the methods were 
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investigated as recommended by Shah et al. (2000). Validation criteria were met by both 
methods (II, Section 2.6.; III, Section 2.7.). 
Data analysis. Maximum concentration (Cmax) and time to peak concentration (tmax)
were obtained directly from individual time-versus-plasma-concentration curves. 
Pharmacokinetic parameters assessed (Siphar®, Simed, France) were absorption rate 
constant (ka), area under the concentration-time curve (AUC0-), apparent elimination half-
life (t½) and mean residence time (MRT). AUC0- values were calculated using the 
trapezoidal method. The method of Wagner and Nelson was used to estimate the apparent 
absorption rate constant (ka). Rate of absorption was also evaluated by means of the ratio 
Cmax/AUC. Statistical analyses were carried out using Student’s paired t-test or Wilcoxon’s 
non-parametric test (for tmax values). When results in different groups of volunteers were 
compared, Student’s t-test relating to independent groups or the Mann-Whitney non-
parametric test (for tmax values) was used. 
Table 3. Compositions of granules in bioavailability studies. For groups 1 to 3 the drug was 
ibuprofen (300 mg), for groups 4 to 6 furosemide (40 mg). 
Study II  Group 1             Group 2 Group 3 Group 4 
Drug  60% 60%  60% 60%  60 b 60 b 60 b 60%  60% 
MCCh Mw 150 kDa  40%  30%   35% 37.5%  40 b 40 b 40 b 40%  30% 
Enteric polymer a - 10%  5% 2.5%   -  -  -   -  10% 
Coating aa - - - - 5% 10% 20% - -
Study III Group 5 Group 6  
Drug  20%  5%   5% 5 bb 
MCCh Mw 150 kDa  80%  95%    -  -  
MCCh Mw 240 kDa   -  -   95% 95 bb 
Tartaric acid   -  -    - 5%   
a Enteric polymer in granules matrices;  
aa Enteric polymer as granule coating, b Polymer to drug ratio 40:60 in granule matrices; 
bb Polymer to drug ratio 95:5 in granule matrices, granules prepared from masses containing 95% of 
MCCh and 5% of furosemide by replacing 5% of the mass with tartaric acid. 
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4.5.2. Gamma scintigraphic investigations (IV–V) 
Three groups of five healthy male volunteers participated in the gamma scintigraphic 
studies. Their weights varied from 62 to 97 kg and their body mass indices (BMI) from 19 
to 27 kg m-2. Informed consent to participation in the studies had been obtained in writing. 
The investigations were carried out in accordance with International Conference on 
Harmonization (ICH) Good Clinical Practice Guidelines and the Declaration of Helsinki 
(World Medical Assembly, 1964) and subsequent amendments. The study protocol had 
been approved by the Ethics Committee of Helsinki University Hospital (HUS) and the 
Finnish National Agency for Medicines. The studies were carried out in HUS Nuclear 
Medicine Division, which has a radiation safety licence issued by STUK (Radiation and 
Nuclear Safety Authority of Finland). Safety requirements were set in accordance with the 
guidelines established by STUK. The ALARA (as-low-as-reasonably-achievable) principle 
was observed, and exposure to radiation was minimised in every situation. 
Procedure. Compositions of study formulations are described in Table 4. Granules 
were dispensed in size-0 gelatine capsules (Ph.Eur.) by volume. The masses of the contents 
of individual capsules were 260 mg (Formulation 1), 290 mg (Formulation 2) and 370 mg 
(Formulation 3). Each capsule contained 4 mg of 152Sm2O3 in the granules. The 152Sm was 
activated in a thermal neutron flux to the gamma emitting nuclide 153Sm (t½ 46.3 hours), 
using a 250kW TRIGA Mark II nuclear research reactor (General Atomics, USA) at the 
VTT Technical Research Centre of Finland. Gamma scintigraphic studies were carried out 
48 hours after neutron activation. This time period allowed decay of unwanted 
radioisotopes; primarily 24Na. Gamma spectra and radioactivity of 153Sm were measured to 
determine the safety of the formulations used in the in vivo studies in healthy volunteers. 
Safety requirements were met for every formulation (IV, Section 3.2.). 
Table 4. Compositions of study formulations in gamma scintigraphic studies (IV and V). 
The granules were dispensed into size-0 gelatine capsules, each containing 4 mg of 
samarium oxide. 
Ingredient Formulation 1 Formulation 2 Formulation 3 
MCCh Mw 150 kDa 95% 40% - 
Lactose 3.4% 58.6% 96.4% 
Sm2O3 1.6% 1.4% 1.1% 
PVP - - 2.5% 
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A capsule containing the granules was administered to each volunteer in a sitting 
position, with 180 ml of water, after the subject had fasted overnight for at least 12 hours. 
The volunteers were not allowed to eat or drink during the imaging period. Anterior and 
posterior images, each of one-minute duration, were recorded continuously for the first     
30 minutes, by means of a dual-head gamma camera (ADAC Forte, ADAC Laboratories, 
USA), after which six images, each of one-minute duration, were recorded every               
15 minutes for the next three to four hours. During imaging each subject lay supine 
beneath the gamma camera. At other times they could move freely. 
Data analysis. Regions of interest (ROI) relating to the stomach (IV and V) or 
oesophagus (V) were drawn manually on gamma images, and gamma counts relating to 
ROIs were calculated using Hermes software (version 3.7, Nuclear Diagnostics, Sweden). 
Geometric means of counts in paired anterior and posterior images were calculated. 
Gastric emptying of the formulations was expressed in terms of remaining relative counts 
(RELcounts) in each ROI as a function of time. Lag times before onset of gastric emptying 
were obtained directly from individual gastric emptying curves. RELcounts between 0.90 and 
0.10 were used to determine the gastric-emptying rate constant (k) by means of linear 
regression analysis. Times at which half of the granules had left the stomach (t50%) were 
used in evaluating gastric residence times. Statistical analyses were carried out using non-
parametric Kruskal-Wallis analysis of variance. 
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5. Results and discussion  
5.1. In vitro characteristics of MCCh formulations 
The various grades of MCCh and conventional chitosan retarded release of the slightly 
soluble drug substances ibuprofen and furosemide from granules, and exhibited fairly 
marked tendencies to adhere to oesophageal mucosa in vitro, suggesting that the chitosans 
studied could be used to prepare slow-release formulations that would also be 
mucoadhesive. Gel formation by chitosan and its retardant effects on drug release, and its 
mucoadhesive capacity could be controlled by altering the grade of chitosan used. Other 
formulation-related variables that affected drug release were the nature of the drug, the 
amount of chitosan used, and the natures of other excipients in granules. The pH of the 
environment influenced the effects of altering these variables. The main results from the    
in vitro studies are shown in Table 5. 
Table 5. Effects of altering formulation variables and environmental factors on the in vitro 
characteristics of formulations containing different grades of chitosan. 
Variable Effect  
Chitosan •Crystallinity  MCCh formed gels most efficiently and had a more marked 
retardant effect on drug release than conventional chitosan (I), 
no effect on mucoadhesive capacity of chitosan (III)  
•Mw Increase in the Mw of MCCh decreased drug release rate (I, III) 
and increased mucoadhesive capacity of chitosan (III) 
 •DD DD of MCCh had no significant effects on drug release rate (I) 
or mucoadhesive capacity of chitosan (III) 
 •Amount Increasing the amount of MCCh decreased drug release rate (I, 
III). With slightly soluble acidic drug substances the effect could 
be opposite at pH levels that were only slightly acidic (I) 
Model drug Slow-release granules were obtained only when using slightly 
soluble drug substances (I–III) 
Environmental pH The lower the pH the more marked were gel formation by 
chitosan and retardant effects on drug release (I, III) 
Other excipients  The slow-release characteristics of chitosan granules could be 
modified by use of enteric polymers in granule matrices or as 
coatings (II) and by use of organic acids in granule matrices (III) 
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5.1.1. Gel-forming ability of MCCh 
Hydration of chitosans in granules and consequent gel formation by the chitosans resulted 
in swelling of the granules, which made it possible to determine gel-forming abilities of the 
chitosans via measurements of granule diameters (I). Granules containing MCCh increased 
more in diameter than corresponding granules made from conventional chitosan (I, Fig. 3), 
indicating that hydration and subsequent gel formation takes place more efficiently with 
MCCh than with conventional chitosan. Gel formation was greatest when pH levels were 
markedly acidic. On the other hand, the less efficient gel formation by conventional 
chitosan resulted in more rapid granule degradation. 
Gel formation by chitosan in granules (Orienti et al., 1996) and tablets (Mi et al., 
1997) is known to depend on pH because of the cationic character of the polymer. The 
results of our in vitro studies indicate that the crystallinity of chitosan could also affect its 
gel-forming properties. A particular property of MCCh is its ability to take up substantial 
amounts of water on hydration (Struszczyk, 1987). Our findings support the idea that this 
property could be reflected in the efficacy of gel formation by MCCh in granule 
formulations. It is well known that pronounced gel formation by a hydrophilic polymer is 
beneficial when slow-release, matrix-type dosage forms are being developed. This has 
been seen, e.g., in studies with HPMC (Alderman, 1984). The property is usually related to 
marked retardant effects on drug release. Our findings therefore suggested that MCCh 
might be better than conventional chitosan as a gel-forming excipient in matrix-type 
dosage forms. The fact that MCCh forms gels most readily at acidic pH levels make it of 
potential value in formulations intended to release drugs slowly in the stomach. 
5.1.2. Effects of grade of MCCh on release and mucoadhesive 
characteristics of chitosan formulations 
Results of further studies indicated that drug release from chitosan granules could be 
controlled by altering the crystallinity of the chitosan used, e.g. by using MCCh grade or 
the more amorphous conventional chitosan (I). Altering the properties of MCCh used 
affected both the slow-release and mucoadhesive characteristics of formulations (I, III).         
In this respect the important property of MCCh grade was its molecular weight. 
MCCh versus conventional chitosan. The mechanism of drug release from chitosan 
granules was regarded as non-Fickian diffusion, on the basis of exponent (n) values (I, 
Tables 3 and 4). Such a mechanism can be explained on the basis of control of drug release 
through gel formation by chitosan, and thereafter both by diffusion of drug through the gel 
and gel erosion. On the basis of the value for kinetic constant (k), drug release was most 
retarded with MCCh in the granules (I, Tables 3 and 4; MCCh grades A and C versus 
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conventional chitosan grade D), as expected from the results of studies of gel formation        
in vitro. The greatest retardant effect on drug release was achieved with the MCCh grade 
which had also a pronounced ability for gel formation. The granules concerned contained 
40% of MCCh with a degree of deacetylation of 75% and molecular weight of 150 kDa        
(I, grade A), and ibuprofen. These in vitro results indicate that increasing the crystallinity 
of chitosan could make its retardant effects on drug release from matrix-type formulations 
more marked, as a result of increasingly efficient gel formation by the chitosan. Better 
slow-release dosage forms might be obtained through use of MCCh rather than 
conventional chitosan. On the basis of these promising results an application has been 
made for a patent relating to slow-release granule formulations containing MCCh     
(Finnish Pat. Application. FI20000780, 2000). 
In studies of chitosans as mucoadhesive excipients, the various grades of MCCh and 
conventional chitosan exhibited fairly marked mucoadhesive tendencies (III). Forces of 
detachment of chitosan tablets from isolated oesophagus preparations were always 
statistically significantly greater (about 2.5- to 6-fold, p < 0.01) than those for the enteric-
coated reference tablet. MCCh and conventional chitosan had equally strong capacities to 
adhere to mucosal tissue (III, Fig. 1; grades II and III versus grade I). It is known that the 
properties of a polymer relating to hydration and gel-forming can affect its mucoadhesive 
capacity (Junginger, 1991). The finding that MCCh had a particularly pronounced ability 
to form gels suggested that MCCh and conventional chitosan might differ in relation to 
their mucoadhesive properties. Results of studies relating to technical applications of 
MCCh have also indicated that the reactivity of MCCh is greater than that of conventional 
chitosan (Struszczyk and Kivekäs, 1992). This property could theoretically result in MCCh 
adhering to mucus to a greater extent than conventional chitosan. However, neither of 
these two properties of MCCh were reflected in terms of mucoadhesive strength of 
chitosan in our studies using isolated oesophagus preparations. This finding suggests that 
chitosan crystallinity had no effect on the mucoadhesive properties of the chitosans 
studied. MCCh and conventional chitosan could both be valuable excipients in the 
development of mucoadhesive formulations. 
Effects of the Mw and DD of MCCh. The properties of MCCh formulations could be 
controlled by using MCCh of different molecular weight but not by using MCCh of 
different degree of deacetylation. The retardant effects of MCCh on drug release from 
granules (I, Fig. 4; III, Fig. 2) and the mucoadhesive capacity (III, Fig. 1) were most 
marked with MCCh of highest molecular weights (Mw 150 kDa and 240 kDa). These 
findings are similar to those in previous studies, in which decreases in rates of release of 
drug from granules (Goskonda and Upadrashta, 1993) and increases in the mucoadhesive 
capacities of chitosan (Lehr et al, 1992) as chitosan molecular weight increased were 
reported. The findings are understandable, because increases in the molecular weight of 
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MCCh markedly increase viscosities of gels formed (I, Fig. 1). Increases in the viscosity of 
chitosan gels result in increasingly retarded drug release (Kristl et al., 1993), and could 
enhance the mucoadhesive properties of the polymer gel (Junginger, 1991). As the chain 
length of the polymer increases penetration of polymer chains into the mucus layer could 
also increase (Peppas and Buri, 1985). In our studies using isolated oesophagus 
preparations, forces of detachment of chitosan tablets increased 2.5-fold as the molecular 
weight of the MCCh increased from 150 kDa to 240 kDa (III, Fig. 1; 0.75 ± 0.29 N (grade 
II); 1.85 ± 0.60 N (grade IV), p < 0.01).  
In contrast, degree of deacetylation of MCCh had no significant effects on drug 
release (I, Fig. 4) or the mucoadhesive properties of formulations (III, Fig. 1). However, 
MCCh of low molecular weight had unexpectedly good mucoadhesive properties (III, Fig. 
1). This might be explained on the basis that the reactivity of amino groups is high with 
chitosans of low molecular weight because the amino groups are easily accessible in the 
structures of such polymers (Sabnis and Block, 2000). If so, effects of degree of 
deacetylation on the mucoadhesive capacity of chitosan could be particularly evident with 
chitosans of low molecular weight. In a recent study by Sabnis et al. (1997) it was found 
that drug release could also be controlled by changing the degree of deacetylation of 
chitosan. However, Sabnis et al. used chitosans of very low molecular weight (20 kDa), 
which might explain why the findings differ from those in our study. In the studies 
reported here, effects of altering degree of deacetylation on drug release were studied using 
only MCCh grades of high molecular weight (I; grade A versus grade C). 
It was concluded from the results of our in vitro studies that MCCh grades of high 
molecular weights were likely to behave best in formulations intended to release drugs 
slowly in the stomach, and such grades were therefore chosen for studies in vivo. Such 
grades of chitosan had marked retardant effects on drug release and strong mucoadhesive 
capacities in vitro. For the first bioavailability studies (II) MCCh of molecular weight of 
150 kDa was available. Later, MCCh of 240 kDa was also used. 
5.1.3. Effects of drug solubility and amount of MCCh on release 
characteristics of chitosan formulations  
Effect of drug solubility. Drug solubility was found to affect the slow-release characteristics 
of MCCh granules substantially (I and II). Model drugs which are slightly soluble in 
acidic environments (I and II; ibuprofen and furosemide) were relatively slowly released 
but retardation of release of a readily soluble drug (I; paracetamol) was minimal. This 
finding is similar to findings in previous studies of granules containing conventional 
chitosan. Slow release from formulations containing slightly soluble drug substances, e.g. 
indomethacin and diclofenac has been reported (Miyazaki et al., 1988a,b; Tapia et al., 
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1993) but preparation of slow-release formulations of a readily soluble drug substance 
(theophylline) has been found difficult (Henriksen et al., 1993). 
Release of ibuprofen at pH 5.8 was slower than release of furosemide from 
corresponding MCCh formulations (II, Figs. 1 and 3; 40% MCCh of Mw 150 kDa). At      
pH 5.8 furosemide, which is a stronger acid (pKa 3.9) than ibuprofen (pKa 5.3) dissolves 
more easily than ibuprofen. Retardant effects of MCCh on drug release were most marked 
when gel formation by the MCCh took place at markedly acidic pH levels, when the 
granules had been hydrated at pH 1.2 prior being subjected to dissolution testing at pH 5.8 
(III, Fig. 3). This result was expected, because gel formation by MCCh in granules had 
been found to be most marked at acidic pH levels (I, Fig. 3), and pH level affected the 
viscosity of MCCh gels (I, Table 2). Gels prepared in a buffer at pH 1.2 were found to be 
markedly more viscous than gels prepared in a buffer at pH 5.8. Our results are similar to 
findings in studies relating to conventional chitosan (Goskonda and Upadrashta, 1993; Mi 
et al., 1997). The ability of MCCh to retard drug release most efficiently at acidic pH 
levels could be valuable in relation to development of formulations intended to release 
drugs slowly in the stomach. 
Effect of amount of MCCh. Rate of drug release could be controlled by varying the 
amount of MCCh in granules. The extent of the effect depended on the model drug 
concerned, and pH. Results relating to paracetamol, which dissolves readily regardless of 
pH throughout the physiological pH range, differed from those with ibuprofen and 
furosemide, which are slightly soluble at acidic pH levels. Increasing the amount of MCCh 
decreased rate of paracetamol release from granules (I, Fig. 8). This finding is 
understandable because increasing the amount of MCCh markedly increases the viscosities 
of gels formed by MCCh (I, Fig. 1). However, even incorporation of a substantial 
percentage of MCCh in the granules (60%) did not result in a satisfactory slow-release 
formulation for paracetamol. This finding was similar to that of Henriksen et al. (1993), 
who studied a readily soluble drug (theophylline) in granules containing conventional 
chitosan (high Mw, DD 77%). Henriksen et al. concluded that gel formation by chitosan 
would have to be more pronounced for retardant effects on drug release to be marked. 
However, the results of our study show that even use of a grade of chitosan that has good 
gel-forming properties did not result in slow release of a readily soluble drug substance. 
In contrast, formulations containing ibuprofen and furosemide, which are slightly 
soluble at acidic pH levels, exhibited satisfactory slow-release properties in vitro. 
Increasing the percentage of MCCh in the granules decreased rate of drug release, but only 
when gel formation by MCCh took place at a markedly acidic pH level, when the granules 
had been hydrated at pH 1.2 prior being subjected to dissolution testing at pH 5.8 (III, 
furosemide). When dissolution testing took place at pH 5.8 with no pre-treatment, high 
percentages of MCCh were associated with highest release rates (I, Fig. 7; ibuprofen; III, 
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Fig. 3; furosemide). One mechanism of action could be that high amounts of MCCh in 
granules increase pH levels of the gels formed (I, Fig. 2), with consequential increases in 
rates of dissolution of the acidic drugs studied. This mechanism could come into play in 
slightly acidic environments, in which gel formation by MCCh is less efficient, with drugs 
that are weak acids. 
The conclusion from the results of the in vitro studies was that slow-release granules 
are likely to be achievable only if the drugs concerned are slightly soluble in acidic 
environments, like ibuprofen and furosemide. The granules studied might behave best as 
slow-release formulations if they were administered to subjects in a fasted state. The 
granules would then be exposed to an acidic gastric milieu, and gel formation by MCCh 
would be expected to be most efficient and its retardant effects on drug release most 
marked. However, administration of granules to individuals in a fasted state would be 
likely to restrict the extent to which the granules could be used. In an attempt to overcome 
this disadvantage small amounts of acidic excipients (2.5 to 10% of tartaric and citric 
acids) were incorporated in granules, in the hope of enhancing gel formation by MCCh and 
ensuring slow release of acidic drugs even at pH levels close to neutral. Addition of these 
acids did not, however, have the desired effect. A marked retardant effect on drug release 
occurred only if MCCh had formed a gel in a markedly acidic environment (III, Fig. 4). 
5.2. Release characteristics of MCCh formulations in vivo 
5.2.1. Bioavailabilities of drugs from MCCh granules; effects of 
amount and molecular weight of chitosan 
MCCh granules were evaluated as slow-release dosage forms in human subjects in a fasted 
state. The granules were administered in gelatine capsules. A formulation containing 40% 
of MCCh of molecular weight 150 kDa was a satisfactory slow-release dosage form of 
ibuprofen, as determined from tmax value. The mean tmax was 2.9 ± 1.1 hours (II, Table 1). 
With conventional dosage forms, maximum ibuprofen concentration in plasma occurs after 
only about one hour (Davies, 1998). Results of studies with furosemide showed that the 
slow-release properties of the formulations studied depend significantly on the drug 
concerned. Furosemide absorption from granules similar to those that had released 
ibuprofen slowly was fairly rapid (II, Fig. 4 versus Fig. 6). The mean tmax for furosemide 
from granules containing 40% of MCCh was only slightly higher (not statistically 
significant) than the mean tmax for a conventional furosemide tablet (II, Table 3). Slight 
increase in tmax could be explained by the fact that drug absorption from MCCh granules 
was subject to a lag time (II, Fig. 6). It was obvious that results of in vitro studies could not 
allow adequate prediction of how formulations would behave in human subjects.  
35
Attempts were made (III) to retard rate of release of furosemide from granules by 
incorporating higher percentages of MCCh (80 to 95%) and by using MCCh of higher 
molecular weight (240 kDa). Although decreases in rates of release of drug had been noted 
in the in vitro studies (III, Fig. 2), it was found that tmax did not change significantly (III, 
Table 2). However, amounts of furosemide absorbed, as determined from AUC0- and Cmax 
values, were lower as in vitro release rates decreased. An obvious explanation for these 
findings is that as rate of release of furosemide from granules decreased, most of the drug 
in the granules had moved beyond the “absorption window” for furosemide in the upper 
gastrointestinal tract. There was no change in tmax, because furosemide is poorly absorbed 
once it has passed its “absorption window”. 
Little information has previously been available on the behaviour in vivo of slow-
release chitosan formulations, especially with chitosan as the only excipient. The results of 
one of the first studies to be carried out in animals indicate that slow-release formulations 
might be obtainable by using chitosan in granule matrices (Miyazaki et al., 1988a). 
Increasing the percentage of chitosan (Mw or DD not stated) in granules from 33 to 66% 
increased tmax for indomethacin, which is slightly soluble and readily absorbed. However, 
the effect was not statistically significant in a small group of animals (see Section 1.3.2. for 
details). The results of bioavailability studies with MCCh formulations also indicate that 
use of chitosan could allow simple preparation of slow-release dosage forms of slightly 
soluble drugs. In our study in human volunteers, absorption of ibuprofen was markedly 
retarded by MCCh. The results of our studies with furosemide, which is absorbed only in 
the upper gastrointestinal tract, suggest, however, that MCCh can be utilised in preparation 
of slow-release formulations only if the drug concerned is absorbed throughout the 
gastrointestinal tract. 
Slow release of a drug from a formulation is beneficial if, e.g., there is a need to 
prevent high peak concentrations of the drug in plasma and it is desirable instead for drug 
concentrations in plasma to be approximately constant over a long period. A satisfactory 
slow-release dosage form of ibuprofen was obtained when granules containing 40% of 
MCCh (Mw 150 kDa) were administered in gelatine capsules to subjects in a fasted state. 
The formulation did not, however, meet the criterion for a prolonged-release formulation, 
because the apparent elimination half-life (t½) for ibuprofen did not change markedly. It 
was 2.4 ± 0.5 hours (II, Table 1), which is fairly similar to the half-life of the drug 
substance itself (~ 2 hours). Incorporation of higher amounts of MCCh or MCCh of higher 
molecular weight in the granules might result in greater retardation of drug release. This is 
suggested by the results of our studies relating to furosemide. 
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5.2.2. Effects of other excipients in MCCh granules  
Attempts were made to make MCCh granules that not only released drugs slowly but also 
acted as prolonged-release formulations. It could be desirable for drug release from a 
dosage form in vivo to be so slow that it is the rate-limiting step in drug kinetics, i.e. very 
slow absorption would restrict the rate of elimination of the drug. In such a case, the 
increase in the apparent half-life of the drug substance would allow a longer interval 
between doses. This could be beneficial in particular in relation to drug substances the 
elimination half-lives of which are short. If the aim were to decrease rate of release of drug 
in vivo, incorporation of higher percentages of MCCh would undoubtedly be one of the 
first steps to be tried. However, incorporation of high percentages of excipients in 
formulations is impractical if a high dose of drug is also required. An alternative means of 
preparing prolonged-release formulation could be incorporation of a chitosan of high 
molecular weight. MCCh grades of molecular weights greater than 150 kDa were not 
available during the early stages of our studies in vivo (II). We therefore tried other 
approaches foreseen when the study strategy was planned. 
The effects of incorporating enteric polymers (2.5 to 10%) in MCCh matrices or 
employing them as granule coatings (5 to 20%) were studied with granules containing 
ibuprofen (II). It was aimed that the polymers, which are insoluble at low pH levels, would 
reinforce the gels formed by the MCCh and control release of drug in the stomach. In other 
experiments, tartaric acid (5%) was added to the matrices of granules containing furosemide 
(III). The aim in this case was to retard release of drug further by enhancing gel formation 
by MCCh, and to ensure that the drug was released slowly even at pH close to neutral. 
Only incorporation of enteric polymer in MCCh granule matrices was found to have 
any effect in vivo. Absorption of ibuprofen could easily be retarded by including enteric 
polymer in granules (II, Fig. 4, Table 1). There were statistically significant differences        
(p < 0.05) in relation to the rate parameters ka, tmax, MRT and Cmax/AUC between granules 
containing only MCCh (40%, Mw 150 kDa) and granules in which 10% of the MCCh in 
the matrices had been replaced with enteric polymer. The marked increase in apparent t½
for ibuprofen indicated that absorption had become the rate limiting step in drug kinetics, 
and that a prolonged-release formulation had been achieved. Apparent t½ values were        
2.4 ± 0.5 hours for granules containing only MCCh and 4.9 ± 2.0 hours for granules in 
which 10% of the MCCh had been replaced by enteric polymer (p < 0.01). A two-fold 
increase in t½ allows the interval between doses to be doubled. The results demonstrate that 
incorporation of small amounts of enteric polymers in granule matrices makes it possible 
to prepare prolonged-release MCCh formulations simply. However, the need for different 
kinds of chitosan grades to be on the market is obvious. 
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5.3. Retention of MCCh formulations in the stomach 
5.3.1. Information obtained via bioavailability studies 
Because furosemide is absorbed only in the upper parts of the gastrointestinal tract (Staib 
et al., 1989), the results of the bioavailability studies with MCCh formulations containing 
furosemide indicated whether the formulations were gastro-retentive (II, III). If the drug 
was released in the stomach, amounts of furosemide absorbed would be similar to or 
greater than those after administration of a conventional formulation. 
The mean AUC0- for furosemide from granules containing 40% of MCCh (Mw
150 kDa) (3450 ± 1180 `g l-1 h) was only slightly smaller (not statistically significant) than 
that from a conventional tablet (3800 ± 941 `g l-1 h) (II, Table 3). The bioavailability of 
furosemide was high, despite a lag time in relation to absorption (~ 30 minutes). These 
findings suggested that the MCCh granules had been retained in the stomach, and led to 
extension of the patent application relating to MCCh formulations (Finnish Pat. 
Application FI20000780, 2000) for gastro-retentive drug delivery (International Pat. 
Application WO01/76562 A1, 2001). However, the results of the following studies (III) 
were less promising. Amounts of furosemide absorbed decreased as in vitro release rates 
decreased, when a relatively high amount of MCCh (80 and 95%) or MCCh of relatively 
high molecular weight (240 kDa) was incorporated in granules (III, Figs. 2 and 5, Table 2). 
When the amount of MCCh (Mw 150 kDa) in the granules was 95%, the mean AUC0-
(2700 ± 1070 `g l-1 h) for furosemide was 29% lower than the AUC0- for a conventional 
tablet that had been determined in study II. Clear et al. (2001) reported similar decreases in 
amounts of furosemide absorbed when drug release took place in the proximal intestine 
instead of the stomach (comparing events after conventional tablets had been released from 
an Intelisite® capsule in the duodenum and after oral administration of tablets). The 
findings relating to the granules that contained 95% of MCCh (Mw 150 kDa) obviously do 
not suggest substantial retention in the stomach. With a formulation containing the same 
percentage of MCCh of higher molecular weight (240 kDa), the decrease in AUC0- was 
more marked (50%), indicating that much of the furosemide had passed the “absorption 
window” before it had been released from the formulation. It is obvious that the granules 
had remained in the stomach for too short a time in relation to the release rate of the drug. 
The bioavailability studies were useful in determining the properties of MCCh 
formulations and indirectly helped evaluation of their potential as gastro-retentive systems. 
Although the MCCh grades studied exhibited fairly marked mucoadhesive capacities       
in vitro, no similar effect was evident from the results of the bioavailability studies.         
The correlation between the results of in vitro and in vivo studies was especially poor in 
relation to MCCh of molecular weight 240 kDa. Although this grade was found to adhere 
most strongly in the in vitro studies (III, Fig. 1; grade IV), the bioavailability of furosemide 
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was lowest from formulations that contained MCCh of Mw 240 kDa (III, Table 2).             
This finding suggests that no substantial adhesion of MCCh to gastric mucosa had            
taken place. Further studies that would provide direct information of the fate of              
MCCh formulations in the human gastrointestinal tract (such as gamma scintigraphic 
investigations) were needed. 
5.3.2. Gamma scintigraphic investigations 
Preliminary studies. Only MCCh grades the properties of which did not change    
markedly during neutron activation were usable in formulations for gamma scintigraphic 
investigation. The effects of irradiation on MCCh (Mw 150 kDa and 240 kDa) were 
therefore studied in vitro (IV). It was found that irradiation did not affect the properties of 
MCCh of molecular weight 150 kDa (IV, Figs. 1a and 2a). However, the MCCh grade 
with the highest molecular weight (240 kDa) was particularly sensitive to irradiation. Gels 
were formed less readily by this grade of MCCh following irradiation, resulting in more 
rapid drug release (IV, Figs. 1b and 2b). The effect become more marked as the irradiation 
dose increased. These findings are in accordance with findings in previous studies 
indicating that irradiation can result in degradation of polymers with glycoside linkages 
(e.g. ethyl cellulose (Waaler et al., 1997), HPMC and pectin (Ahrabi et al., 1999) and 
MCCh (us in study IV)).  
Gamma scintigraphic investigations. MCCh of molecular weight 150 kDa was 
selected for use (IV). Because we had found that the amount of MCCh in granules affected 
the bioavailability of furosemide (see Section 5.3.1.), the same percentages (40 and 95%) 
of MCCh were used in formulations in gamma scintigraphic investigations. 
The reference formulation (lactose granules in gelatine capsules) passed fairly 
rapidly through the stomach (IV, Fig. 5, Table 4). After a short lag time before onset of 
gastric emptying (IV, Table 3) it took from 15 minutes to about one hour for the granules 
to be cleared from the stomachs of five volunteers, on the basis of the rate constant (k) (IV, 
Table 4). In most cases gastric emptying took place in small and frequent boluses.              
In contrast, passage of MCCh granules from the stomach was prolonged in three occasions           
out of nine (IV, Figs. 3 and 4), in one subject of the four who received a formulation 
containing 95% of MCCh, and in two subjects of the five who received a formulation 
containing 40% of MCCh. Maximum individual t50% values (times at which half of the 
granules had left the stomach) were 2.1 hours (95% of MCCh, Subject 1) and 2.3 hours 
(40% of MCCh, Subject 5) (IV, Table 4). For the reference formulation, t50% varied from 
0.2 hours to 1 hour (mean 0.5 ± 0.3 hours). From the gamma images it was concluded that 
the time MCCh granules remained in the stomach was prolonged because the formulation 
had adhered to the gastric mucosa. This is shown in Figure 2 relating to Subject 5, who had 
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Figure 2. Gamma scintigraphic images showing the fates of granules containing 40% of 
MCCh of Mw 150 kDa in the stomach of Subject 5. (a) Gelatine capsule containing the 
granules has not disintegrated (4 minutes). (b) Capsule has disintegrated and granules have 
become attached to gastric mucosa (12 minutes). (c) Granules still attached to the gastric 
mucosa but some have passed through the pylorus and reached the small intestine              
(2.5 hours). (d) Most granules have left the stomach (4 hours). 
been given granules containing 40% of MCCh. The granules were released from the 
gelatine capsule in approximately 5 minutes, after which about two thirds of the granules 
(IV, Fig. 4; Subject 5), became attached to the gastric mucosa (corpus region), and 
remained attached two hours after administration. However, in the other six volunteers 
who had received MCCh granules (containing 40 or 95% of MCCh), radioactivity in the 
stomach region declined fairly rapidly. The curves relating to passage of MCCh granules 
from the stomach were rather similar to those for the reference formulation (IV, Figs. 3 and 
4 versus Fig. 5). It was obvious that in most cases the MCCh granules did not adhere to the 
gastric mucosa or that adhesion was not strong. 
The results of the gamma scintigraphic investigations are in good accordance with 
the results of the bioavailability studies. In the latter, amounts of furosemide absorbed 
decreased as rate of release of drug from the granules declined, indicating that the granules 
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did not remain long enough in the stomach in relation to release rate of drug. The results of 
the gamma scintigraphic investigations showed that MCCh formulations rarely adhere to 
gastric mucosa. The results also showed that there were no significant differences in the 
times for which formulations containing different amounts of MCCh (40 and 95%) 
remained in the stomach. The finding in bioavailability studies that the AUC0- for 
furosemide was higher for granules containing the lowest amount of MCCh can be 
explained by more rapid release of the drug from the formulation concerned. This would 
have allowed furosemide absorption to take place mostly in the upper gastrointestinal tract, 
in the “absorption window”, irrespective of whether the granules had adhered to gastric 
mucosa, and resulted in the higher bioavailability observed. 
It is evident from the results of the gamma scintigraphic investigations that the 
behaviour of MCCh formulations studied as gastro-retentive systems is not sufficiently 
reproducible. Although the results of several in vitro studies (Lehr et al., 1992; He et al., 
1998; Gåserød et al., 1998; and us in study III), and results of a few studies in animals 
(Remuñan-López et al., 2000; Shimoda et al., 2001) suggest that chitosans could be of 
value as excipients that adhere to the mucosa of the gastrointestinal tract, we found no 
evidence from studies in human subjects that chitosan formulations could be used for 
gastro-retentive drug delivery. Prolonged gastric residence times of formulations were rare, 
even though the study conditions had been designed to eliminate factors that could hinder 
gastro-retention (e.g., the study was carried out in fasting volunteers). 
Various physiological and formulation-related factors could explain why the systems 
did not work as expected. One formulation-related factor is that the granules were 
administered in gelatine capsules. It has been suggested that administration of formulations 
containing mucoadhesive polymers in gelatine capsules makes the gastro-retentive 
properties of the formulations less marked (Harris et al., 1990b). The gelatine in the 
capsule shell could interact with the mucoadhesive polymer during dissolution, and 
diminish the adhesive properties of the formulation. The consequences of administering 
granules in gelatine capsules require study. It is nevertheless obvious that administration of 
granules in capsules is more convenient than their administration loose. Another factor that 
could affect in vivo behaviour is granule size. In a recent study in mice, Remuñan-López et 
al. (2000) suggested that chitosan granules might be gastro-retentive if they were very 
small, i.e. if microparticles that could be taken into the mucosa were prepared. 
However, physiological factors might be most significant in making the in vivo 
behaviour of formulations erratic. There are substantial differences between conditions in 
in vivo and in vitro studies. It is therefore not surprising that many polymers known to 
possess mucoadhesive properties in vitro (e.g. the polyacrylic-acid-based polymers 
investigated by Khosla and Davis (1987) and Harris et al. (1990a) and the MCCh studied 
by us) fail to exhibit gastro-retentive properties in studies in human beings. The 
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physiological conditions in the stomach may be such that it is difficult to make 
formulations containing mucoadhesive polymers remain there for long. The layer of mucus 
to which adhesion could take place is continually eroding, and this could hinder 
persistence of adhesive systems in the stomach (Allen et al., 1993). Exposure of chitosan to 
soluble mucins in the stomach lumen before it has a chance to interact with mucus gel 
layer could also adversely affect the adhesive properties of formulations (Gåserød et al., 
1998). Although results of studies in animals (e.g. the rat, dog) relating to mucoadhesion of 
polymers have been promising, little tendency to adhesion has been found in studies in 
man (Harris et al., 1990a,b; Davis et al., 1993). Because there are always limitations on 
extrapolation of results of animal studies to human beings, studies in human subjects are 
needed. In the studies described here, gamma scintigraphy allowed information about the 
fate of formulations in the gastrointestinal tracts of the human subjects to be obtained 
directly, and made it possible to reach conclusions about whether the MCCh formulations 
studied had potential as gastro-retentive dosage forms. 
5.4. Additional information provided by gamma scintigraphy 
on the behaviour of MCCh formulations in vivo 
Gamma scintigraphy provided additional information about the behaviour of the MCCh 
formulations studied in the gastrointestinal tract. Adherence of the formulation to the 
oesophagus was noted in one volunteer. It is well known that adherence of a dosage form 
to the oesophagus can result in oesophageal injury, which can be severe. More than 70 
drugs in common use have been reported to be associated with oesophageal disorders 
(Jaspersen, 2000). Failure of formulations to move rapidly through the oesophagus is a 
problem associated not only with pharmaceutical products but also with non-medical 
natural products, in which the presence of substantial amounts of gel-forming polymers 
can result in oesophageal obstruction (Opper et al., 1990). Our finding of adherence of an 
MCCh formulation to the oesophagus indicates problems that might be associated with use 
of formulations of the kinds studied. A detailed case report has therefore been published 
(V). Results relating to the passage of the formulation from the stomach of this volunteer 
were excluded from analysis (IV) because the situation was clearly so different from 
situations in the other subjects. 
The formulation concerned consisted of granules containing 95% of MCCh of 
molecular weight of 150 kDa, in a gelatine capsule. The capsule adhered initially to the 
distal oesophagus (V, Fig. 1). The gelatine shell started to disintegrate within five minutes 
of administration, after which radioactivity in the oesophageal area started to decline as the 
contents of the capsule moved towards the stomach (V, Fig. 2). However, about two thirds 
of the radioactivity remained detectable in the oesophageal region for 1.75 hours. This 
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could be explained on the basis that not only the gelatine shell but also MCCh granules 
were adhering to the oesophageal mucosa after disintegration of the capsule shell had 
commenced. This explanation is consistent with the results of in vitro studies (III) in which 
MCCh exhibited a fairly marked tendency to adhere to the isolated porcine oesophagus 
(III, Fig. 1). 
Normally, oesophageal transit times of dosage forms are short, only some 10 to           
20 seconds (Channer and Virjee, 1985; Wilson et al., 1988; Burton et al., 1995). It is, 
however, well known that adhesion of dosage forms to the oesophagus can occur in up to 
20% of cases, the risk of adhesion being high, e.g., with gelatine capsules that become 
sticky as they hydrate. It is interesting that the results suggest that gel-forming chitosan 
also adhered to the oesophageal mucosa. This finding suggests that use of chitosan may 
need to be avoided in formulations containing drug substances associated with 
oesophageal injury, particularly if gelatine capsules are also used. Caution might also be 
needed in relation to non-medical natural products containing chitosan. Amounts of 
chitosan in such products are often high, daily intakes usually amounting to several grams. 
The substantial amounts of gel-forming chitosan and the large size of the products could 
make them likely to stagnate in the oesophagus, and increase risk of oesophageal 
obstruction.  
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6. Conclusions 
In vitro and in vivo studies were undertaken on the properties of MCCh, a highly crystalline 
grade of chitosan base, as an excipient. The most significant information to emerge from 
this study related to the in vivo behaviour of MCCh formulations in humans. One major 
defect in previous studies is that most have relied exclusively on in vitro methods to 
determine the properties of chitosan-based formulations. In the study described here the 
results of dissolution and mucoadhesion tests in vitro often did not allow adequate 
prediction of how MCCh formulations would behave in human subjects. This underscores 
the importance of conducting biopharmaceutical studies in human volunteers at an early 
stage during the evaluation of new excipients. 
 
The following conclusions can be drawn from the results of this study: 
1. Various grades of MCCh and more amorphous conventional chitosan were useful 
in preparing granules from which drug release in vitro was controlled by formation 
of gels in acidic and slightly acidic environments. The release mechanism was drug 
diffusion through the gel and gel erosion. All the chitosans studied had fairly 
marked mucoadhesive capacities in vitro. 
2. Gel formation by chitosan in vitro, retardant effects of chitosan on drug release and 
mucoadhesive capacities of chitosan depended on its physicochemical properties. 
MCCh was superior in terms of gel formation and accordingly had a more marked 
retardant effect on drug release than conventional chitosan. The molecular weight 
of MCCh was important: the greater the Mw the slower the release and the greater 
the strength of adhesion to mucus. Degree of deacetylation of MCCh had no 
significant effect. All these findings indicate that MCCh of high Mw should be 
valuable as an excipient in preparing slow-release dosage forms that are also 
mucoadhesive. 
3. Drug release in vitro could also be controlled by altering the amount of MCCh in 
the formulation. Increasing the MCCh content decreased the release rate after gel 
formation at acidic pH. The solubility of the drug concerned substantially affected 
the slow-release characteristics of the granules. Slow release took place only with 
drugs having low solubility at acidic pH levels (ibuprofen, furosemide). Even 
incorporation of high amounts of MCCh did not result in slow release of the readily 
soluble drug (paracetamol). 
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4. The results of bioavailability studies in human volunteers showed that MCCh 
granules can be used in gelatine capsules to prepare slow-release dosage forms of 
slightly soluble drugs, provided these are absorbed throughout the gastrointestinal 
tract (such as ibuprofen). With furosemide, which is absorbed only in the upper 
gastrointestinal tract, there were no significant differences in tmax between 
formulations, even though differences in release rates had been seen in vitro. The 
amounts of furosemide absorbed were affected, indicating that the granules did not 
remain long enough in the stomach in relation to the release rate of the drug. These 
findings demonstrate the importance of carrying out studies in vivo. 
5. Incorporation of small amounts of an enteric polymer into MCCh granule matrices 
considerably prolonged ibuprofen absorption. This finding suggest that a 
combination of chitosan, which forms gels, and a polymer insoluble at acidic pH 
levels could be valuable in the development of prolonged-release formulations. 
6. The results of gamma scintigraphic investigations showed that the behaviour of 
MCCh formulations as gastro-retentive systems is insufficiently reproducible. 
Although MCCh exhibited a fairly marked mucoadhesive capacity in vitro, 
adhesion of MCCh onto gastric mucosa in vivo was rare. These results also 
demonstrate the importance of biopharmaceutical studies. Gamma scintigraphy 
was valuable in studying the fate of formulations in the human stomach. 
7. The results of gamma scintigraphy revealed that a formulation containing MCCh 
had adhered for a considerable time to the oesophagus in one volunteer. This 
finding indicates that there could be problems associated with the use of MCCh 
granules, particularly if the granules are administered in gelatine capsules. It also 
serves as a reminder that drugs known to be capable of damaging the oesophagus 
should not be used in formulations where there is the risk of oesophageal adherence. 
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